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Abstract
Computational Hybrid Systems for
Identifying Prognostic Gene Markers of Lung Cancer
Ying-Wooi Wan
Lung cancer is the most fatal cancer around the world. Current lung cancer prognosis and
treatment is based on tumor stage population statistics and could not reliably assess the risk for
developing recurrence in individual patients. Biomarkers enable treatment options to be tailored
to individual patients based on their tumor molecular characteristics. To date, there is no
clinically applied molecular prognostic model for lung cancer. Statistics and feature selection
methods identify gene candidates by ranking the association between gene expression and
disease outcome, but do not account for the interactions among genes. Computational network
methods could model interactions, but have not been used for gene selection due to
computational inefficiency. Moreover, the curse of dimensionality in human genome data
imposes more computational challenges to these methods.
We proposed two hybrid systems for the identification of prognostic gene signatures for
lung cancer using gene expressions measured with DNA microarray. The first hybrid system
combined t-tests, Statistical Analysis of Microarray (SAM), and Relief feature selections in
multiple gene filtering layers. This combinatorial system identified a 12-gene signature with
better prognostic performance than published signatures in treatment selection for stage I and II
patients (log-rank P<0.04, Kaplan-Meier analyses). The 12-gene signature is a more significant
prognostic factor (hazard ratio=4.19, 95% CI: [2.08, 8.46], P<0.00006) than other clinical
covariates. The signature genes were found to be involved in tumorigenesis in functional
pathway analyses.
The second proposed system employed a novel computational network model, i.e.,
implication networks based on prediction logic. This network-based system utilizes gene
coexpression networks and concurrent coregulation with signaling pathways for biomarker
identification. The first application of the system modeled disease-mediated genome-wide
coexpression networks. The entire genomic space were extensively explored and 21 gene
signatures were discovered with better prognostic performance than all published signatures in
stage I patients not receiving chemotherapy (hazard ratio>1, CPE>0.5, P < 0.05). These
signatures could potentially be used for selecting patients for adjuvant chemotherapy. The
second application of the system modeled the smoking-mediated coexpression networks and
identified a smoking-associated 7-gene signature. The 7-gene signature generated significant
prognostication specific to smoking lung cancer patients (log-rank P<0.05, Kaplan-Meier
analyses), with implications in diagnostic screening of lung cancer risk in smokers (overall
accuracy=74%, P<0.006). The coexpression patterns derived from the implication networks in
both applications were successfully validated with molecular interactions reported in the
literature (FDR<0.1).
Our studies demonstrated that hybrid systems with multiple gene selection layers
outperform traditional methods. Moreover, implication networks could efficiently model
genome-scale disease-mediated coexpression networks and crosstalk with signaling pathways,
leading to the identification of clinically important gene signatures.
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Chapter 1
Introduction
For the past decades, cancer has been the major health problem to industrialized countries around
the world. Among all types of cancers, lung cancer is the leading cause of cancer-related deaths
[3]. Treatment failure will lead to death in lung cancer. Currently, surgery is the foremost
treatment option for patients with stage I non-small cell lung cancer (NSCLC). However, 35–
50% of stage I NSCLC patients will relapse within 5 years [4, 5]. It remains a critical challenge
to determine the risk for recurrence in early-stage lung cancer patients. Patients at high risk for
recurrence might benefit from adjuvant chemotherapy, whereas those with a low risk for tumor
recurrence might be spared from the side effects of chemotherapy. Following this, another
critical issue in clinics is to determine an individual patient’s predisposition to a specific
anticancer drug. The emerging use of biomarkers may enable physicians to make treatment
decisions based on the specific characteristics of individual patients and their tumor, instead
merely of on population statistics [6].
Microarray technologies present a convenient platform for scientists and clinical
investigators to gain new insights into biology and ultimately for developing clinical applications
[7].

The advancements in microarray technologies lead to promising achievements in the

molecular prediction of individual clinical outcome. Two successful examples include the
commercial gene tests for breast cancer, Oncotype DX [8] and MammaPrint [9, 10]. There have
been a few studies on lung cancer signatures and molecular prognosis by transcriptional profiling
[2, 11-17]. To date, there is no fully-validated and clinically applied model for predicting lung
cancer recurrence [18].
1
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On the other hand, microarray technologies pose a few challenges in computational
techniques for molecular prognosis and diagnosis researches [19]. The first challenge is the high
dimensionality of the data. A typical microarray experiment would be able to profile up to tens
of thousands of genes. This nature of microarray data has complicated major diagnostic and
prognostic breakthroughs [20] and puts a premium on innovative feature selection and data
mining methods. Feature selection methods allow us to select a subset of predictive genes as
biomarkers.

With the discovered biomarkers, we could construct a faster, cost-effective

prognostic or diagnostic classifier with improved performance [21]. The main objective of
feature selection is to remove irrelevant features and retain only the informative features.
Nevertheless, the search of the optimal subset of informative features in the space of all features
is NP-hard. This hard problem becomes more difficult when the microarray data is also small in
sample size and clouded with noisy biological confounding effects [22].
The most intuitive approach to identify candidate marker genes is to rank genes
according to their association with the clinical outcome and select the top ranked genes.
However, studies had shown that individual genes showing strong association with the outcome
are not necessarily good classifiers [23-25]. Moreover, instead of functioning alone, genes and
proteins interact with one another to form modular machines [26]. Ranking-based approaches
that evaluate each gene individually could not model interactions among genes. Therefore, with
the completion of the Human Genome Project, understanding the networks of interactions among
genes had become increasingly important to reveal the molecular basis of disease for biomarker
identification [27].
Currently, various techniques had been applied to microarray studies to identify
biomarkers and construct molecular classifier.

To discovery predictive gene signatures,

statistical methods and feature selection methods is simple and efficient but would not account
for the complex interactive machinery among genes.

On the other hand, network-based

approaches overcome the limitations of statistical and feature selection methods by providing a
closer modeling of genetic interactive nature. However, they might suffer from computational
complexities. Once the set of signature genes had been identified, construction of the molecular
classifier poses another set of challenges. These challenges include assessment of the classifiers’
robustness [19] and the true biological validity of the findings [28]. Combining the limitations of
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various methods with challenges originated from microarray data discussed above, it remains an
open problem in this research domain to develop a methodology to efficiently identify a set of
predictive genes as the biomarker for molecular prognosis or diagnosis.
In this dissertation, we proposed two computational hybrid systems as the robust platform
to identify prognostic gene signatures for lung cancer molecular prognosis. The first hybrid
system combined multiple traditional statistics and feature selection methods in different stages
for gene filtering.

The second hybrid model integrated a novel network model, i.e. the

implication networks based on prediction logic. The integration of the network models in the
second system incorporates the information of gene interactions with major signaling hallmarks
in the identification of prognostic gene signatures. To examine the proposed hybrid system
methodologies, three studies were carried out. The first study examined the first combinatorial
framework with traditional statistics and feature selection methods. It demonstrated that the
combinatorial scheme of using different traditional methods to filter genes in multiple stages
identify better gene signatures when applying these methods alone. The second hybrid system
that is built upon the innovative implication networks was investigated in the second and the
third study. The second study employed the network-based system to explore the prognostic
signatures discovery in the whole genomic scale. Extensive gene signatures for lung cancer with
better prognostication than all published signatures were identified in this study. Instead of the
entire genome, the third study applied the network-based model in a smaller scope: genes
significantly associated with lung cancer survival and smoking status.

This leads to the

identification of prognostic gene signatures specific to the smoking lung cancer patients. The
implication networks efficiently and accurately model gene coexpression patterns perturbed by
the disease outcome or other factor, such as smoking status.

Furthermore, it leads to

identification of prognostic genes tightly involved in signaling pathway.
The remainder of the proposal is organized as follows. Chapter 2 presents the related
work with focuses on various gene selection methods. These methods would be described and
their strengths and weakness would be summarized and discussed. Chapter 3 describes the first
study of hybrid models with statistical and feature selection methods. Chapter 4 includes the
second study with the integration of implication networks in the hybrid model in genomic scale.
Chapter 5 presents the study of using the implication networks in the identification of a smoking-
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associated signature. Chapter 6 compares the implication networks employed in our studies with
two network models, i.e. Boolean implication networks and Bayesian networks. Finally, the last
chapter, Chapter 7 discusses the contributions of our studies and the future works for the
methodology.

Chapter 2
Related Work
In recent two decades, with advancements in high-throughput biotechnologies and knowledge in
genomic profiling such as microarray technologies, researches are able to investigate prognostic
factors of cancer using genomic data such as gene expression values. These studies involved
identification of gene signatures as biomarkers, construction of molecular prognostic models
using the identified biomarkers, and validation of the findings for clinical applications. This
chapter provides a review of the methods and works related to our studies. Since public data was
use in our studies, a brief description of the few data sets used is included at the end of the
chapter. The first three sections will discuss the methods for genomic signatures identification in
three categories: ranking-based gene selection methods (2.1), network-based methods (2.2), and
regularized linear models (2.3). A thorough discussions on the few major methods reviewed in
the first three sections is given in Section 2.4. Statistical methods and bioinformatics tools used
to validate the survival and biological aspect of the computational findings will be discussed in
Section 2.5. Section 2.6 describes of the few public data sets used in our studies. Finally, we
summarize the chapter with Section 2.7.

5
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2.1 Ranking-based Gene Selection Methods
2.1.1 Introduction
In several microarray studies, genes are ranked according to their association with the clinical
outcome, and the top ranked genes are identified as the gene signature and included in the
prognostic classifier [8, 11, 12, 15, 29, 30]. The top rank genes could be either a fixed number of
top tanked genes (such as top 10% of the ranked list). Alternatively, a threshold can be set on
the ranking criterion and the genes whose criterion exceeds the threshold are selected as
signature genes. Methods to study and rank the association of genes could be grouped into two
major categories: statistical methods and traditional feature selection methods. This section will
briefly describe various methods found in these two categories.

2.1.2 Statistical Methods
The traditional practice to study the gene association to the clinical outcome from microarray
data is to identified genes that differentially expressed between two clinical states, for example
between the disease state and normal state. One approach to identified differentially expressed
genes is to compute the gene expression fold change between the two states for each gene and
assess the observed fold change with statistical significance test. The commonly used statistical
significance test is the conventional t-tests, which provides the probability (P) that the computed
changes in expression occurred by chance [31]. Genes that pass certain predetermined threshold
of fold change and statistical significance constitute the list of prognostic genes [32].
Microarray data is usually small in sample size with large number of genes. This poses a
challenge in determining significance level using P-value from conventional t-test. For example,
the traditional statistical significant level of P = 0.05 will lead to discovery of 1,000 false
positive genes by chance in a microarray experiment with 20,000 genes. On the other hand, a
more stringent threshold such as P = 0.001 will decrease false positives but result in high false
negatives which will lead to failure in discovering a lot predictive genes [33]. It is a multiple
hypothesis testing problem to determine if a gene has significantly different changes amongst
large number of other genes. Multiple testing correction methods such as Bonferroni correction
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is too conservative to be applied in microarray experiment. For example, it would require a gene
with P < 0.05/20,000 in order to be declared significant, which is so small that hardly any genes
could achieve that threshold. Therefore, statistical methods used to control the false discovery
rate (FDR) are used instead. Such a method commonly used in microarray analysis is significant
analysis of microarrays (SAM) [34].
SAM is used to identify genes with statistically significant changes in two different
biological states. It accounts for the multiple hypothesis testing problems in microarray analysis
by estimating the FDR for the set of significant genes based on permutation test. In SAM, a
modified t-test, or known as gene-specific t-test is used. For each gene, it computes the ratio
change in gene expression relative to standard deviation, known as the “relative difference”:
d (i ) =

x I (i ) − xU (i )
s (i ) + s 0

(1)

where x I (i ) and xU (i ) are defined as the mean expression for gene (i) in states I and U,
respectively. s(i) is the standard deviation in expression for gene (i) and s0 is a positive constant
used to ensure the relative difference d(i) is independent of the gene expression.
The procedure carried out in SAM is depicted in Fig. 2.1, the observed relative
differences for all the n genes are ranked into ascending order. Null distribution of the relative
difference of each gene is generated by random permutations of samples’ class labels for π times.
In each iteration p, null relative difference dp(i) for each genes are ranked into ascending order as
well. From the null distribution of relative differences, the expected relative difference dE(i) for
gene (i) is computed by averaging the null relative differences from all iterations:

∑
(i ) =

π

dE

p =1

d p (i )

π

(2)

The expected relative differences are then ranked into ascending order and plotted against
the observed relative differences. From the scatter plot, genes with differences between the
observed and expected relative differences greater than the threshold delta (Δ) are identified as
significant genes (or known as “called significant” genes), which could be defined as the set T:
T = {i : d (i ) − d E (i ) > Δ}

(3)
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In each iteration, falsely discovered genes are those whose null relative difference dp(i)
exceeds the horizon cutoffs (du and dl) of observed relative difference for genes called
significant found from the scatter plot.
The estimated FDR relative to the set of significant genes T is defined as the ratio of the
average number of genes falsely discovered from all π permutations over the total number of
genes called significant. Mathematically, this could be represented as:

∑

π

FDR =

p =1

{i : d p (i ) > du or d p (i ) < dl}

π
T

(4)

Figure 2.1. Procedures of SAM

In data analysis involved survival outcome, such as survival status after surgery, censored
cases often occur often due to failure in follow up. Using SAM or other discrete-class learning
methods, they need to be removed from the analysis as the exact survival outcome for these
observations were not known. In microarray data analyses where observations are limited, it’s
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important to include as many available observations as possible to strengthen the statistical
power of the study. Therefore, methods that could include all observations yet accounting for
censored cases would be preferred from methods that redefine the problem as binary class
problem by removing censored cases.

Statistical survival analysis methods such as Cox

proportional hazard model would account for censored cases. Univariate Cox proportional
hazard model analyzes how each gene changes relative to survival status. Gene that passed
certain predefined significance threshold or ranked tops according to the statistical significance
would be identified as interesting genes that are related to survival outcome [11, 15].
Cox proportional hazard model, or usually known as Cox model, is a regression model
proposed by D.R. Cox [35]. It’s commonly used in survival analysis to study the relationships
between predictors (or known as covariates) and the survival outcome. In survival analysis, the
hazard at time t, is the probability of an event (such as death) at time t, given survival up to time t
[36], which can be defined as:
h(t ) =

number of subjects experiencing the event at time t
number of subjects at risk starting time t

(5)

In univariate Cox model, the hazard definition is extended to be proportional hazard,
which is the probability of an event at time t, given survival up to time t, and for a specific value
of a predictor, x:
h(t | x) = h0 (t ) × exp( β ⋅ x)

(6)

where h0(t) is known as baseline hazard function. It is the probability that subjects will
experience the event when the predictor is zero. Hazards for observations of two survival states
could be defined as:
h(t | x = x1 ) = h0 (t ) × exp( β ⋅ x1 )

(7)

h(t | x = x 2 ) = h0 (t ) × exp( β ⋅ x 2 )

(8)

Thus, the ratio of the two hazards is obtained by:

h(t | x = x1 ) h0 (t ) × exp( β ⋅ x1 )
=
h(t | x = x 2 ) h0 (t ) × exp( β ⋅ x 2 )

(9)

= exp( β ⋅ ( x1 − x 2 ))
Assume the change of the predictors is one unit; it gives us the estimated degree of effect of the
predictor on survival, known as hazard ratio:
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HR = exp( β )

(10)

The statistical significance of the estimated hazard ratio is assessed by Wald test, under
the hypothesis that the coefficient (β) is zero [37], which is analogous to the fact that the
predictors has no effect on survival giving a HR of 1. Nevertheless, the number of genes is much
larger than the number of samples available. The value indicates the significance of the genes
ranked by univariate Cox model need to be corrected for multiple hypothesis testing.

2.1.3 Feature Selection Methods
Traditional feature selection methods used in machine learning applications are not commonly
employed in genomic studies. Random forest is one of the feature selection methods used to
select predictive genes in genomic studies [38-41]. Random forest uses both bagging and
random variable selections in the algorithm to construct the ensemble of classification trees.
Specifically, each of the classification trees is built using a bootstrap sample of the data, and each
split of the tree is based on a random subset of the variables [42]. Random forest could be used
for variable selection because in addition to classifications, random forest assesses the
importance of each variable in the algorithm. The decrease in a tree splitting criterion, the Gini
index and the decrease of permutation accuracy are implemented in random forest as measures to
evaluate the importance of variables with respect to the outcome [43, 44]. The out-of-bag (OOB)
error rate from the classification could be used as a criterion to select the final set of variables
through an iteration random forests [38]. Since the tree split is based on random subset of
variables on a bootstrapped sample, it enables random forest to work efficiently in microarray
data where number of variables (genes) is much larger than the number of observations [38].
Random forest could select a smaller set of variables which could also achieve comparable
prediction performance than other classifiers with larger set of variables [39, 41, 44], especially
in data with large amount of noise. These properties of random forest are preferred in genomic
studies with noisy high-throughput microarray data. One issue with random forest is the stability
of the results given [38].

Multiple sets of selected variables that are equally good in

classification performance would be produced by random forest. The lack of uniqueness and
overlapping genes in the resulting selected genes will lead to questions on the biological
interpretability of the results [45].
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Principle Component Analysis (PCA) is another common method used to reduce the
feature space dimensionality by transforming the data to a new coordinate system, or feature
space. Each coordinate (called the principle component) is a linear combination of the original
features [46]. The first few principle components yield the greatest variance present in all the
original features and hence usually selected as the new feature for classification.

One

disadvantage of the projection method is that all of the original input features need to be retained
[47]. It was proposed to perform gene selection through a variable selection strategy based on
PCA [48]. A variation of PCA, such as the generalized and nonlinear kernel PCA (KPCA) was
also proposed to reduce dimension of the microarray gene expression data prior to classification
[49].
Relief is another method that could be used for feature selection because it would assess
the importance of each variable in differentiating samples between two classes and provide the
ranking accordingly. The first Relief algorithm was proposed by Kira and Rendell [50]. An
extended version with more reliable probabilities estimation was later proposed by Kononenko et
al. [51], known as Relief-F. In the extended version, instead of calculating the weight of features
based on the nearest hit and miss of the randomly selected sample, k-nearest hits and k-nearest
misses of the randomly selected sample are used. As depicted in Fig. 2.2, Relief evaluates the
importance of a variable by repeatedly sampling an instance and checking the value of the given
variable for the k-nearest instances from the same and different classes. The values of the
variables of the nearest neighbors are compared to the sampled instance and used to update the
relevance weights for each variable.

1.
2.
3.
4.
5.
6.
7.
8.

set all weights W[A] := 0.0;
for i := 1 to n do
begin
randomly select an instance R;
find nearest hit H and nearest miss M;
for A:= 1 to #all_attributes do
W[A] := W[A] – diff(A, R, H)/n + diff(A,R, M)/n;
end;
Figure 2.2. The Relief algorithm [51].

2. Related Work

12

An approximation of the weight of attribute A computed by Relief could be written as:
W[A] = P(different value of A | k - nearest miss)
- P(different value of A | k - nearest hit)

(11)

When the algorithm stops, Relief assigns more weight to those variables that have the
same value for instances from the same class and differentiate between instances from different
classes [52, 53].

2.1.4 Discussion
Among the few ranking-based gene selection methods, t-test and fold change is the simplest and
most intuitive technique in selecting genes differentially expressed with respect to disease
outcome. However, it is sensitive to the gene-specific variances and the estimates suffer more in
small sample [54, 55]. These gene-specific variances were adjusted in SAM through a new
statistics measurement, the gene-specific t-test, or known as the relative difference [34].
Moreover, with t-test, multiple testing problem arises from the large number of genes in
microarray data and poses high risk in false positive. To address to this problem, repeated
measurements of statistics from permutations are used in SAM to control for amount of false
positives. Nevertheless, the permutations cause SAM more computationally expensive than ttest.

Instead of evaluating the differentiation of expression between two disease states,

univariate Cox model evaluates the discriminative power of genes with respect to survival
outcome, which is over a series of time points. This is the strength of univariate Cox model over
t-test and SAM in studies involved survival data. Theoretically, SAM could be generalized to

implement survival analysis method by defining the gene-specific t-test in a different way.
There is no available tool for such implementation.
Small sample size is one of the key challenges in microarray data studies. To obtain less
biased estimates from small sample, machine learning methods such as random forest and Relief
employed randomization and repeated measurements. When sample size is small, bagging with
bootstrapped aggregating was shown to be able to improve the performance of unstable
estimators, such as the classification and regression tree (CART) [56]. Random forest employs
bagging in the algorithm and have shown to provide good performance in microarray data with
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small samples and large variables [38]. Random forest is more flexible as it could be used to
rank the genes by providing a variable importance measure for each gene and also could provide
a subset of predictive genes through classifications. This presents a convenient framework for
removing redundant genes. On the hand, Relief does not remove redundant features. In term of
computational time, Relief is faster than random forest and other feature selection methods as it
avoids any exhaustive or heuristic combinatorial search. The Relief algorithm is in linear time to
the number of features and number of samples selected. Although Relief has been applied in a
wide aspect of applications, ranging from feature selection before model constructions to provide
feature importance guide in other algorithm [57], it is not commonly used in microarray studies.

2.2 Network-based Methods
2.2.1 Introduction
Fundamental mechanisms of molecular functions are based on interactions among genes and
proteins [26, 58]. Therefore, it’s important to understand the genes interaction networks in order
to gain further insights to the relationships between genes and diseases. Molecular network
analysis using computational network models has led to promising applications in identifying
new disease genes [59], discovering disease-related sub-networks [60], and classifying diseases
[61]. Computational network models that have been developed for molecular network analysis
can be roughly categorized into three classes: logical model to demonstrate the state of entities
(genes/proteins) at anytime as a discrete level; continuous models to represent real-valued
molecular network processes and activities over continuous timescale; and single-molecule
models to simulate small regulatory networks and mechanisms [62]. Since our studies involved
implementing novel computational network models in biomarkers discovery using microarray
data, a few logical network models commonly used for molecular network studies will be briefly
discussed in this section.
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2.2.2 Artificial Neural Networks
Artificial neural networks (ANNs) are computational models consist of set of highly
interconnected nodes. The structure and functions of ANNs are modeled with the motivation
from the biological neural systems, where each node in the ANNs portray the biological neurons
[63]. ANNs are typically organized in layers of nodes, where each node interconnected with one
another with a connected line. The lines represent the relationships between the nodes and each
connection has an associated weight to describe the strength of the relationship. ANNs are
generally described in three layers: input layer, hidden layer, and output layer (Fig 2.3). The
input layer contains nodes to which the input is presented. The output layer is where the final
predictions/ answers are retrieved. The hidden layer, which could contain more than one layer, is
where the processing is done on the incoming data and feed the output to the next layer.

Figure 2.3. Structural diagram of a general artificial neural network.

To construct an ANN model representing the data, back-propagation algorithm is the
most common algorithm used to learn the weights. Specifically, the algorithm starts with a
random weight, then iterates through the training data set and updates the weights to reduce the
error on each observation. The algorithm stops when weights converge, or when the error rate
passes a certain threshold [63, 64]. Once the weights are learned, the modeled ANN could be
used to obtain prediction on new input. An example of this process in software high-risk
program detection is given in Fig. 2.4. The training phase of modeling an ANN is relatively time
consuming, but the prediction phase is typically straightforward and fast [63]. The learning rate
parameter in the back propagation algorithm could be tuned to control the speed of the training
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process. However, it would affect the generalization of the constructed ANN, leading to overfitting the data or too generalized with low precision.
Artificial neural networks were first used in artificial intelligence applications to interpret
complex real-world problems, such as speech synthesis, facial recognition, and handwriting
recognition [63]. Nowadays, ANNs could be found in a wide range of applications, including
applications in biomedical fields and microarray studies. A few examples include modeling
classifier for diagnostic or prognostic prediction [65-68], learning and modeling interactions
among genes from expression data [69] .

Figure 2.4. Construction of artificial neural networks for high-risk programs detection. [64]
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2.2.3 Bayesian Networks
Bayesian networks, which also known as Bayesian belief networks or belief networks, are
graphical models used to represent the joint probability distributions of a set of random variables
and the conditional dependence relationships among the variables based on Bayesian probability.
Bayesian networks have been a popular framework for encoding uncertain knowledge in expert
systems [70].

Bayesian networks had been applied and shown to be useful in various

applications, ranging from manufacturing control, price forecasting, diagnosis, automated vision,
to bioinformatics [71-74] .
Bayesian network is a directed acyclic graph (DAG) where the nodes representing
random variables and edges representing direct relationships between the connected variables.
In the Bayesian network, each node has an associated conditional probability table (CPT)
denoting the conditional probabilities of the node given all possible combinations of its parents.
For nodes without parent, prior probability of the node is specified [75]. Markov assumptions on
conditional independence among variables are hold in Bayesian networks. Markov assumptions
state that variable Xi is considered independent of its non-descendants, given its parents and joint
distribution could be decomposed into the product form [76]. For a given set of random
variables X = {X1, …, Xn}, the joint distributions represented by the Bayesian networks could
thus be defined as:
n

P( X 1 ,..., X n } = ∏ P( X i | Pa G ( X i ))

(12)

i =1

where PaG(Xi) is the set of parents of Xi in the Bayesian network. Fig. 2.5 gives an
example of the Bayesian network with five variables.

Figure 2.5. An example of Bayesian network structure.

2. Related Work

17

The Markov independencies among the variable in the Bayesian network in Fig 2.5 are
I(A;E), I(B;D | A,E), I(C; A,D,E|B), I(D;B,C,E|A), and I(E;A,D). The joint distribution of the five
variables specified by the Bayesian network is:
P(A, B,C, D, E) = P(A)* P(B | A, E)* P(C | D)* P(D | A)* P(E)

(13)

A scoring function is used to evaluate how well a built Bayesian network matches the
data. The score computed could be used as the criterion in the Bayesian network that best
represent the probability distributions of the attributes in the data. Given a sufficiently large
number of instances, the learning procedure will converge and lead to the exact network
structure up to the correct equivalence class [77]. This process of searching for the optimal
network in the space of directed acyclic graphs is a NP-hard problem.

Multiple search

algorithms such as hill-climbing, beam search, or simulated annealing could be used to search for
the optimal network. Although these methods provide only suboptimal solution, in which only
the local maximal Bayesian network is obtained, it had been shown to give good performance in
practice. Another approach for more efficient learning process is sparse candidate algorithm
[77], in which a subset of variables was chosen as the set of candidate parents and the search was
restricted to networks in which the candidate parents of a variable can be its parents.
Bayesian networks could be used to interpret causal relationships among variables by
imposing more stringent interpretation of the edges: the parents of a variable are its immediate
causes. In the causal interpretation, variable is considered independent of its earlier causes, given
the values of its parents. This is known as the causal Markov assumptions. This causal
interpretation of Bayesian networks is a natural interpretation for biological models. For
example, in genetic pedigree: once we know the genetic makeup of the individual’s parents, the
genetic makeup of her ancestors is not informative about her own genetic makeup. [76].

2.2.4 Implication Networks
Similar as Bayesian networks described in the last section, implication networks are also
probabilistic graphical models representing the relationships among the variables. In the
implication network, each node represents a variable and the edge between pair of nodes
represents the type of implications existing between the pair of variables. Instead of acyclic as in
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Bayesian networks, implication networks allow cyclic relation, which is an important property
over Bayesian networks for biological networks studies.
The first formalism of implication networks was proposed by Liu and Desmarais [78],
which is based on binomial distribution. This formalism had not been applied to any aspect of
biological studies. Another formalism of implication networks based on prediction logic was
proposed by Guo et al. [1], where prediction logic based on formal logic rules was used to derive
successful implication relations.
There exist six implication relations between any pair of dichotomous variables (Fig. 2.6).

Figure 2.6. Six most important implication rules relating two dichotomous variables.

Each table in Fig 2.6 is a contingency table (Table 2.1) where each cell represents the
number of co-occurrences. For example, cell NA˄B indicates the number of samples where both
variables A and variable B are true. The shaded cells of the contingency tables in Fig. 2.6
represent the errors for the corresponding implication rule. For example, A˄¬B is the error cell
for the implication rule A ⇒ B , N A˄¬B represents the number of error occurrences. Cell A˄¬B is
erroneous for the rule A ⇒ B because in an ideal case, if the implication A ⇒ B is the true
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relationships between A and B, then we would never expect to find the contradiction case where
A is true but not B.
Table 2.1. Contingency table of two variables for N empirical samples.

B
A NA˄B
¬A N¬A˄B

¬B
NA˄¬B
N¬A˄¬B

To derive the implication relation between each pair of variables in the dataset, a
modified U-Optimality method [79] was used in the implication induction algorithm (Fig. 2.7).
The Implication Induction Algorithm by Guo et al. [1]
Begin
Set a significant level ∇min and a minimal Umin
For nodei, i ∈ [0, vmax – 1] and nodej, j ∈ [i+1, vmax]
(Note: vmax is the total number of nodes)
For all empirical case samples N
Compute a contingency table as in Fig. 2.6
N11 N12
Mij =
N21 N22
For each relation type k out of the six cases, find the solution
Max Up
Subject
Max Up ≥ Umin
to
∇p ≥ ∇ min
∇error cells > ∇ non - error cells
If the solution exists, then return a type k relation
End
Figure 2.7. Implication induction algorithm based on prediction logic.

In the contingency table Mij of the induction algorithm (Fig. 2.7), N11 indicates number
of samples where both i and j occur to be true, N12 is when i is true but not j, N21 is when j is true
but not i, and N22 is when both i and j are not true.
In the induction algorithm, Up is the scope of the implication rule, representing the
portion of the data covered by the implication relation, and ∇p is the precision of the implication
rule, representing the prediction success of the corresponding implication relation. For a single
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error cell, where Nij is the number of error occurrences, scope Up, and precision ∇p are defined
as:
Up = Uij =

Ni. * N . j

∇p = ∇ij = 1−

N2

N ij
N *Up

(14)

(15)

For the rule types where there are multiple error cells, they are defined as:
Up = ∑∑ ωij * U ij
i

(16)

j

⎛ ωij *U ij
∇p = ∑∑ ⎜⎜
Up
i
j ⎝

⎞
⎟⎟∇ ij
⎠

(17)

where ωij = 1 for error cells; otherwise, ωij = 0.
Based on the contingency table for variable A and B (MAB) (Table 2.1), the scope and
precision for each of the six implication rules in Fig. 2.6 are defined as follows.
For positive implication, A ⇒ B ,
U A⇒ B = U

∇ A⇒ B = ∇

=
A∧¬B

N A * N¬ B
N2
N

A∧¬B
=1−
¬
A∧ B
N * U A⇒ B

(18)

(19)

Similarly, for forward negative implication, A⇒ ¬B ,
U

∇

= U A∧ B =
A⇒ ¬B

N A * NB
N2

N A∧ B
= ∇ A∧ B = 1 −
¬
A⇒ B
N *U
A⇒¬B

For inverse negative implication, ¬ A ⇒ B ,

(20)

(21)
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U¬

∇¬

A⇒ B

A⇒ B

N ¬A * N ¬B
N2

(22)

N¬ ¬
A∧ B
=
−
1
A∧¬B
N *U ¬

(23)

=U ¬

=∇¬

A∧¬B

=

A⇒ B

For negative implication, ¬ A⇒ ¬B ,
U¬

∇¬

=U ¬
=
A⇒¬B
A∧ B

N¬ A * N B
N2

N¬
A∧ B
=
∇
=
−
1
¬A∧ B
A⇒¬B
N *U ¬
¬

(24)

(25)

A⇒ B

For positive equivalence, A ⇔ B ,
U A⇔ B = U

+U¬
=
A∧¬B
A∧ B

∇ A⇔ B = 1 −

N A * N ¬ + N¬ A * N B
B

N2

N A∧ ¬B + N ¬A∧ B
*N
N A * N ¬B + N ¬A * N B

(26)
(27)

And for negative equivalence, A ⇔ ¬B ,
U

= U A∧ B + U ¬ ¬ =
A⇔¬B
A∧ B
∇

N A * N B + N¬ A * N¬ B
N2

N A∧ B + N ¬ ¬
A∧ B
=
1
−
*N
A⇔¬B
N A * NB + N¬ * N¬
A
B

(28)

(29)

In the implication induction algorithm, the minimum requirement for the scope (Umin) and
precision ( ∇ min ) must be positive values for an implication rule. They are the parameters used
to control the significance level for an implication rule. In our studies, we defined the minimum
requirement for these two parameters to be at least 95% significant (P < 0.05) from one-tail Ztest based on the sample size. In this induction algorithm (Fig. 2.7), the minimum requirements
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for deriving an implication rule are set for both scope and precision, which is different from the
original U-Optimality [79] method, where the minimum requirement is set for precision alone.
An implication rule has high precision when the number of error occurrences is a small
portion of the data covered by the implication rule. An implication rule is successfully derived
from the algorithm if it has the maximum scope, Up and it satisfies the constraint that its scope
(Up) and precision ( ∇p ) are greater than the required minimum values, Umin and ∇ min ,
respectively.

To simplify the computations of the maximization problem, the precision

∇ij value of every error cell must be greater than that of the non-error cells for the corresponding

implication rule [1].
The complexity of the induction algorithm is O(Nv2), where N is the sample size and v is
the number of variables in the dataset (i.e. nodes in the implication networks) [1].
To represent the strength of the implication relation for the connecting pair of variables, a
weight is estimated based on conditional probability. Since each implication rule has a logically
equivalent rule, another weight for the corresponding logical equivalence should be estimated.
Both weights could be derived at the same time by the induction algorithm [1]. Let WI be the
weight associated with the implication rule, WI' is the weight associated with its logical
equivalence. For example, for implication rule A ⇒ B , its logical equivalence is ¬ B⇒ ¬A .
Their respective weights are defined as:
N A∧ B
N A ∧ B + N A ∧ ¬B

(30)

N ¬A∧ ¬B
N A ∧ ¬B + N ¬ A ∧ ¬B

(31)

WI =
WI' =

Given a quintuple representing the implication rule I:

I ∈ I&&, I =< R, N ant , N con ,WI ,WI' >

(32)

where I&& represents the set of all possible implication rules, R represents the implication rule type,
WI and WI' are the weight functions mapping the antecedent node Nant and consequent node Ncon
of the implication rule and their negations to the real number between 0 and 1, which are defined
as:
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WI : N ant × N con → [0,1]

(33)

WI' : ¬N ant × ¬N con → [0,1]

(34)

The formalism of implication networks based on prediction logic integrates formal logic
theory and statistics, which provides conceptual value of prediction analysis in constructing and
evaluating useful statements, particularly in complex multinomial problems with moderate
sample sizes [1]. This feature is essential for clinical applications, in which many clinical
parameters are multinomial and the patient sample size is small. The implication induction
algorithm in Fig. 2.7 is general for discrete datasets. With the expansion of the contingency table
Mij, implication rules can be induced for multinomial datasets, where error cells are those with
the highest precision ( ∇ij values) and satisfying all the constraints. The proposition can then be
induced according to the error set.

2.2.5 Boolean Implication Networks
Recently, another formalism of implication networks, Boolean implication networks

were

constructed to model gene interactions networks in a meta-analysis of microarray data for
multiple species [80]. The implication relations in the Boolean implication networks were
induced based on scatter plots of expression between two genes. On the scatter plots of gene
expressions, a threshold was automatically determined using StepMiner algorithm [81] to
discretize the gene expression level as ‘high’ or ‘low’. Based on the discretized levels, the
scatter plot is partitioned into four quadrants and the implication relation between the two genes
is derived based on the number of data points (occurrences) in the quadrants. The partitioned
scatter plot with four quadrants is analogous to the contingency tables in Fig. 2.6 and Table 2.1,
where the ‘low’ and ‘high’ expression of gene A corresponds to ¬A and A respectively. In order
to derive a successful implication rule between the pair of genes for the Boolean implication
networks, two statistics were tested.

The first statistic tests if the observed number of

occurrences in the sparse quadrant (error cell) is significantly less than the expected number of
occurrences under an independent model, given the relative distribution of low and high values
of both genes. The second statistic estimates the maximum likelihood of the error rate for the
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number of occurrences in the error cell. For example, if the error cell for genes A and B is where
both A and B is low, the observed and expected number of occurrences in the error cell is:
obsreved = N ¬

expected = (

N¬
N

A*

N¬
N

(35)

A∧¬B

B )* N =

N¬ *N¬
A
B
N

(36)

The first statistics and the error rate are thus defined as:
statistic =

expected - observed

error rate = 1 2 * (

(37)

expected
observed observed
+
)
N¬
N¬
A

(38)

B

An implication rule representing the pair of genes is successfully derived if the statistic in
equation (37) is greater than 3 and the error rate is less than 0.1.

2.2.6 Discussion
The four network models reviewed above falls into the first class of computational models for
regulatory network analysis [62], which are logical models. Logical models are suitable for
modeling the interactions among genes from microarray data as they require the least amount of
data compared with other network models, such as single-molecule network models. Although
the logical models are abstract and could only provide qualitative insight to the interactions, they
are simpler to be studied. Other benefits shared by logical models reviewed above are that they
provide good performance in learning from noisy data and provide a framework for inferring
predictions [63, 82, 83].
There are a few limitations with ANNs. The first argument about ANNs is that the
modeled networks are overly complex and difficult to be interpreted. It is like a “black box”
where the weights learned are hard to be understood by humans compared with other rule-based
classifiers [63, 84]. Although it is computationally difficult, the knowledge about the weights
learned could be retrieved in the form of Causal Indices (CI) [84]. Another shortcoming about
ANNs is that they will over-fit the training data and generalize to new data poorly when the
sample size is small. Furthermore, as discussed earlier, it is time consuming in training the
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weights of the networks. This makes modeling genome-wide gene interactions with ANNs
computationally challenging. To our knowledge, there are no applications for the complete
modeling for gene-gene interactions for the whole human genome. On the other hand, unlike
implication networks where the gene expression values would need to be discretized into binary
scale, ANNs could model the interactions of genes at continuous form.
Bayesian network is more commonly known and preferred in molecular network analysis
[58, 73, 74]. Bayesian networks are preferred because it could provide causal relationships
between pair of genes.

More importantly, the noise inherent to biological data could be

accommodated by the probabilistic nature of the formalism of Bayesian networks [74]. A causal
interpretation for Bayesian networks had been utilized to predict genome-wide protein-protein
interactions [73] and model cellular networks [72]. However, it is not viable to evaluate all
possible networks as the number of possible networks grows exponentially in the number of
genes under consideration. Furthermore, owing to the Markov assumption hold in Bayesian
networks, it is not always possible to determine the causal relationships between nodes, i.e., the
direction of the edges [85]. More importantly, the acyclic Bayesian network structure was unable
to model feedback loops, which are essential in signaling pathways [74] and genetic networks
[86-88]. To overcome the acyclic limitation, a more complex scheme, dynamic Bayesian
networks, was explored for modeling temporal microarray data [89, 90]. On the other hand,
implication networks could model cyclic relations. Therefore, the cyclic implication network is
more suitable for studying relationships and interactions of biological networks than Bayesian
networks.
Implication networks and Bayesian networks are both belief networks formalized based
on statistics derived from data. Implication networks are not as commonly known in the research
domain as Bayesian networks. The latest applications of implication networks in the research
domain are the Boolean implication networks, which are proposed as a computational platform
for genomic evolution of genes interactions and discovery of novel biological relations among
genes [80]. It was shown that implication networks is computationally efficient and feasible to
be applied to construct genome-wide networks [80].

Moreover, implications networks are

suitable for genes networks representation because both the symmetric and asymmetric
relationships between pair of genes could be represented with the six implication rules [80],
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where asymmetric relationships could be represented by the first four implication rules
( A ⇒ B , A⇒ ¬B , ¬ A ⇒ B , and ¬ A⇒ ¬ B ); symmetric relationships could be represented by
positive equivalence ( A ⇔ B ) and negative equivalence ( A⇔ ¬B ).

2.3 Regularized Linear Models
2.3.1 Introduction
In general context, linear models are used to study the effects of multiple factors on the response
variable or used to construct a prediction model. In microarray studies, linear models such as
ANOVA or ordinary least square (OLS) linear regression models were used to analyze gene
expression changes or to construct classification models [91, 92]. In this section, we will briefly
review the general properties of linear models and their shortcomings in microarray analyses
through descriptions of two specific regularized linear regression models.
A few properties were desired in linear models for genomic studies. The first property is
to have a good fit in the modeling data but also accurate prediction in new observed data. In
fitting the regression model, when the number of predictors is relatively large, the fitted models
will tempt to overfit the data available but predict poorly in new observed data. The curse of
dimensionality phenomenon with the large p (number of predictors) small n (number of samples)
found in microarray data not only posts a challenge in fitting the models but also makes the over
fitting problem worse [93]. Shrinkage methods were recommended to avoid the overfitting
problem in fitting the regression model in small data sets [94]. The second property desired is to
select the whole group of genes sharing the same biological pathway instead of individual genes
[95]. Furthermore, since most genomic studies involve construction of patient classification
model using the set of genes selected, it is desired for linear models to have a property where the
gene selection method is built into the classification procedure. In this section, lasso and elastic
net, the two regression-based methods with these properties, will be discussed.
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2.3.2 Lasso
Lasso (least absolute shrinkage and selection operator) is a linear regression method proposed by
Tibshirani [96] as a regularization for OLS linear regression. Linear regression model is a model
used to obtain a predicted response ŷ with liner combinations of p predictors x1, … , xp, which
could be formulated as:
yˆ = βˆ0 + x1βˆ1 + ... + x p βˆ p

(39)

The model fitting procedures produce the vector of estimated coefficients βˆ = ( βˆ0 , βˆ1 , ...., βˆ p ) .
Suppose that we have a data of n samples: (xi, yi), i = 1, 2, …, n, where xi = (xi1, …, xip)T
are the predictors and yi are the responses. OLS linear regression estimates the coefficients by
minimizing the residual squared error:
⎡

⎤

n

βˆ OLS = arg min ⎢∑ ( y i − ∑ β j xij ) 2 ⎥
β

⎣ i =1

j

(40)

⎦

OLS often fits the given data well but performs poorly in future data. Thus, alternative
methods for the coefficient estimations were desired. Lasso was proposed as an alternative
estimation method through regularizing the OLS regression model by adding a L1-norm penalty.
In other words, lasso estimates the coefficients by minimizing the residuals sum of squares
subject to a bound on the L1-norm of the coefficients:
⎡

n

⎣

i =1

⎤

βˆ lasso = arg min ⎢∑ ( y i − ∑ β j xij ) 2 ⎥ , subject to
β

j

⎦

∑β

j

≤ t , (t ≥ 0)

(41)

j

which is equivalent to solving the following problem:
⎡ n
⎤
min ⎢∑ ( y i − ∑ β j x ij ) 2 + λ ∑ β j ⎥
β
j
j
⎣ i =1
⎦

(42)

Due to the L1-norm constraint, lasso will assign a zero coefficient to some of the
variables, causing these variables being “dropped out” from the regression model automatically.
Thus, lasso could also be treated as a method for variable selection.
The criterion

n

∑(y − ∑ β
i =1

i

j

xij ) 2 in equation (41) is equivalent to the quadratic

j

equation ( β − βˆ OLS )T X T X ( β − βˆ OLS ) that forms elliptical contours centered around β̂ OLS . Take
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an example with two features as shown in Fig. 2.8A. The L1-norm constraint β1 + β 2 forms the
rotated square. The solution to the above equation is the first point where the contours meet the
rotated square. When it happens at the corner, the corresponding coefficient will be zero (β2 in
this example), which is analogous to dropping the corresponding variable out of the model,
providing a mechanism for automatic variable selection. In practice, one can tune the parameter
t in order for the contours to meet the constraint. As a comparison, the L2-norm penalty

employed in the ridge regression could not provide variable selection mechanism because the
constraint β12 + β 2 2 forms a circle instead of a square (Fig. 2.8B), in which there is no corner
for the contours to hit and hence zero coefficients will rarely occur [96].

Figure 2.8. Geometry of the coefficient estimation for (A) lasso and (B) ridge regression.

2.3.3 Elastic Net
Elastic net proposed by Zou and Hastie [97] is another regularized regression model that could
be used for variable selection by taking the advantage of both lasso and ridge regression. In
elastic net, regularization is done through the combination of L1-norm and L2-norm. The
coefficients are estimated by minimizing the residuals sum of squares subject to a bound on a
function with L1- and L2-norm of the coefficients:
⎡

n

βˆ naiveEN = arg min ⎢∑ ( y i − ∑ β j xij ) 2 + λ1 ∑ β j + λ 2
β

which is equivalent to:

⎣ i =1

j

j

∑β
j

2
j

⎤
⎥
⎦

(43)
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⎡n

⎤

βˆ naiveEN = arg min ⎢ ∑ ( yi − ∑ β j xij ) 2 ⎥ ,
⎣⎢i =1

β

j

⎦⎥

subject to (1 - α )∑ β j + α ∑ β j 2 ≤ t , with α =
j

j

λ2

(44)

λ2 + λ1

The combined constraints for elastic net (at α = 0.5) forms a diamond circle as compared with
the rotating square by lasso and circle by ridge regression in the two-dimensional example (Fig.
2.9).

Figure 2.9. Two-dimensional contour plot of elastic net penalty at α=0.5 (----) as compared with
lasso penalty ( ….. ) and ridge penalty( -- -- --).

The addition of the L2-norm penalty provides grouping effects in addition to the variable
selection feature provided by the L1-norm penalty. In lasso, if multiple variables are closely
important and highly correlated to one another, only one of them will be selected and the other
will be dropped out from the model. This is inappropriate for genomic studies as the groups of
genes sharing the same biological pathway are desired to be identified together as they all
function as a whole. However, the problem of multicollinearity phenomenon in regression exists
as the groups of genes sharing same biological pathway are highly correlated to one another.
With the L2-norm penalty, the group of highly related variables will all be retained in the model
with a more stable estimation; while the unimportant variables will be dropped out from the
model with the L1-norm penalty. With the combined advantages from both penalties, elastic net
is preferred than lasso in genetic studies for variable selections, such as identification of multiple
genetic variants from the whole genome [98].
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Empirical studies showed that the estimation done in obtaining the βˆ naiveEN from
equation (44) incurs double shrinkage [97]. Double shrinkage causes the estimation to perform
well only when the problem is close to either lasso or ridge regression. Thus, it’s known as the
naïve elastic net. In order to correct the double shrinkage problem, a more stable estimation for
elastic net is obtained by rescaling the naïve elastic net coefficients:

βˆ EN = (1 + λ2 ) βˆ naiveEN

(45)

2.3.4 Discussion
Between the two regularized linear models reviewed, lasso is simpler to be interpreted compared
to elastic net and computationally lighter. However, lasso performs poorly in data with high
collinearity [99] and select only one out of the group of genes sharing the same biological
pathway. Although elastic net is more complex, is has all the three properties desired for linear
models in genomic studies introduced at the beginning of the section. Elastic net performs better
than lasso and provide groups mechanism leading to selection of genes sharing the same
pathways. The grouping effects of elastic net could sometime turn into drawback of the method
as it would lead to selection of highly redundant genes and incapable of providing small subset
of predictive genes.

2.4 Critiques of Gene Selection Methods and Our Proposed
Frameworks
Among the various gene selection methods discussed in the previous three sections, rankingbased gene selection methods are the easiest to be implemented.

Despite the efficient

computation time and scalability to the large dimension, ranking-based methods evaluate genes
in isolation, without considering the effect of interactions among genes. Regularized linear
model could capture the interaction effects among genes. However, the interactions limited to
linear relationships. Since genes function through a series of complex interactions, the nonlinear network models would be more appropriate to model the biological networks, such as gene
regulations and genetic pathways. Compared with network-based methods, regularized linear
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models provide better computational complexity; but more computationally expensive than
ranking-based methods.
Implication networks are computationally efficient and easier to be interpreted than
ANNs. Most importantly, implication networks allow cyclic relations. This property makes
implication networks more appropriate than Bayesian networks in studying genomic networks
where feedback loop is common. Nonetheless, implication networks are more computationally
heavier than ranking-based methods.
In summary, ranking-based methods are simple, scalable but do not account for true
interconnecting nature among genes. On the other hand, network-based methods could provide a
closer representation of the true phenomenon among genes but are much more computationally
intensive.

Therefore, we proposed combinatorial framework with different gene selection

methods in multiple stages in order to systematically exploit the benefits while avoiding the
drawbacks of various methods for novel gene signatures identification and better molecular
prognosis. The first proposed combinatorial framework employed a combination of traditional
statistics and feature selection methods. These methods include t-test, SAM, and Relief feature
selection. The second proposed framework was built upon novel computational network models,
i.e., implication networks. Implication networks efficiently model genome-wide coexpression
networks and allow us to utilize signaling pathways for identifying prognostic genes signatures.
Survival prediction classifiers were constructed using the identified biomarkers to predict
clinical outcome in individual patients. Prognostic performance of the classifiers is evaluated
using statistical methods such as Kaplan-Meier (KM) analysis and concordance probability of
estimate (CPE). Topological structure of the coexpression networks derived from implication
networks were evaluated and confirmed with reported molecular interactions in literature.
Bioinformatics tools were used to validate the clinical and biological aspects of the
computational findings. These methods and tools will be introduced in the next section.
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2.5 Validation Methods and Tools
2.5.1 Introduction
A common objective shared by our works and studies is to apply the findings for clinical use in
the future, such as for disease prognosis. In order to apply the findings for clinical use, we
should confirm if the computational findings agree to the true biological phenomenon. Due to
the high cost and risk involves in in-vivo studies, the computational findings would be first
evaluated using statistical methods, bioinformatics tools, or information obtained from genomic
databases before the in-vivo studies. In this section, we will discuss the methods used to
evaluate the performance of the prognostic model, the interactions revealed by computational
network models, and the biological relevance of the gene sets identified.

2.5.2 Prognostic Evaluation
To evaluate the clinical value of the gene signature identified and the survival prediction model
construct, statistical methods such as Kaplan-Meier (KM) survival analysis and concordance
probability estimate (CPE) would be used to validate if the prediction obtained agreed to the true
survival outcome.
Kaplan-Meier (KM) survival analysis is a non-parametric statistical method used to
estimate a survival function from lifetime data [100]. In KM analysis, the survival function is
estimated based on the life-table of the data, where survival time of patients could be of different
length [101]. In collecting clinical outcomes from patients, it is hard to have stringent control on
patients over time and therefore some patients who are valid at the beginning of the study would
become invalid from one particular time onwards. For example, contacts with certain patients
were lost before their death.

These patient samples would be considered censored cases.

Therefore, analysis methods that could consider censoring samples over the time series are
important in survival analysis. Table 2.2 gives an example of the life- table.
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Table 2.2. An example of life-table.

No. of months in
study
0-5
5-12
12-15
16-20
21-30

No. of patients
at risk
10
10
8
5
3

No. of patients
who died
0
1
1
2
1

No. of patients
censored
0
1
2
0
0

KM analysis is also known as the product limit estimator. Based on the life-table, the
survival probability of each interval is estimated as the ratio of number of survival patients over
number of patients at risk. If ni is the number of patients at risk just prior to time ti and di is the
number of patients died at time ti, the KM estimate of survival at time t is the non-parametric
maximum likelihood estimate S(t), which is the product of survival probability of intervals prior
to time t:
n − di
Sˆ (t ) = ∏ i
t < t ni

(46)

i

The plot of the estimated survival function is a series of declining horizontal steps. An
example of KM curve of the estimated based on life table in Table 2.2 is shown in Fig 2.10.

Figure 2.10. Example of Kaplan-Meier curve estimated based on life-table in Table 2.2.

When comparing survival functions of multiple groups estimated from KM analysis, the
Mantel-Cox log-rank test could be used to evaluate the statistical significance between the
survival curves for different groups [101]. For example, if the prognostic classifier predicts
patients into two groups, a KM analysis could be used to estimate the survival function of each
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predicted group and log-rank test is used to test if the two groups are significantly different in
terms of survival. Fig 2.11 give an example of comparing two KM curves.

Figure 2.11. An example of comparing two Kaplan-Meier curves.

In general, concordance probability (CPE) is used to evaluate how the predicted
outcomes of a nonlinear statistical model agreed with the actual outcomes.

Concordance

probability of a pair of bivariate observations (X1, T1) and (X2, T2) is thus defined as:

K X ,T = P(T2 > T1 | X 2 ≥ X1)

(47)

In our studies, we used Cox proportional hazard model to estimate the risk scores of each
subject. Therefore, we would like to evaluate how the risk scores obtained from our model
agreed with the actual survival outcomes of patient samples.

In order to evaluate how

concordant the risk scores estimated is to the actual survival outcomes, the CPE proposed by
Gonen and Heller could be used [102]. This estimation is focused on Cox model and is defined
as:

K ( β ) = P(T2 > T1 | β T x1 ≥ β T x 2 )

(48)

where T is the response variable (the actual survival outcomes of patient samples) and βTx
corresponds to risk scores obtained from the Cox model.
In their estimation, partial likelihood estimator βˆ is used to substitute β and the empirical
distribution of βTx is used to represent the distribution of risk scores. To resolve the asymptotic
nature of the Cox partial likelihood estimator, a kernel function is used for smoothing. The final
estimator used in obtaining the concordance probability of the model obtained would be purely
based on the regression coefficients and covariates from Cox model, without the patients’
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survival time and outcomes. Therefore, this estimation is not sensitive to the censoring cases in
the patient samples.
If the CPE obtained is close to 0.5, it indicates that model has poor predictive
performance on the actual survival outcome (it’s as good as the random chance of tossing the
coin). The model showed better predictive performance when the CPE is approaching closer to
1.

2.5.3 Gene Coexpression Networks Assessment
The gene coexpression networks derived from the implication networks are evaluated on
precision, false discovery rate (FDR), and stability. Precision and false discovery rates evaluate
the biological relevance of the derived coexpression networks. Stability examines if the derived
coexpression relations were stable or unpredictable.
Five gene set collections (positional, curated, motif, computational, and Gene Oncology)
and canonical pathway databases from the MSigDB 1 were used to evaluate the precision and

FDR of the derived coexpression networks. A coexpression relation was considered a true
positive (TP) if the pair of genes belongs to the same gene set or pathway in any investigated
database. If a pair of genes does not share any gene set or pathway, the coexpression relation
was considered a false positive (FP). A coexpression relation was labeled as non-discriminatory
(ND) if at least one gene in the pair is not annotated in a database [103]. Coexpression relations
labeled as ND were excluded in the evaluation as they were not confirmed.
Precision and q-value of the coexpression networks are defined as:
Precision =

TP
TP + FP

(49)

q − value =

FP
TP + FP

(50)

To generate the null distributions of precisions and q-values, class labels of patient
samples in the test data were randomly permuted for 1,000 iterations and the coexpression
networks were derived based on the permuted data. From the null statistics, the statistical
1

http://www.broadinstitute.org/gsea/msigdb/collections.jsp
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significance (P) of the precision is indicated by the chance of getting higher precision from the
null distribution. The FDR of the disease-mediated coexpression networks is the average of qvalue from the null distribution.
The stability of the computationally derived coexpression networks was evaluated with
different subsets of patient samples from the training set in 100 iterations. The stability is defined
as the portion of the coexpression relations obtained from the original data that are retrieved by
using only a random subset of the training data and the full test data.

2.5.4 Topological Validation
To confirm if the interactions obtained from the computational network models truly exists in
biological context, bioinformatics tools and public genes/protein interactions databases would be
used.
Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems, Redwood City, CA) is a
proprietary web-based curated database which provides contents of gene and protein interactions
reported in the literature. The databases and software toolsets weigh and integrate information
from numerous sources, including experimental repositories and text collections from published
literature. Therefore, IPA allows researchers to derive curated molecular interactions, including
both physical and functional interactions, and pathway relevance. In studies related to our work,
IPA enables us to delineate molecular networks of genes interacting with the set of gene
interested and identify the most significant biological processes and functions from the networks
delineated from core analysis. Pathway Studio 2 is another bioinformatics application like IPA to
allow user to carry out pathway analysis based on curated data from literature. Literature
available in Pathway Studio is extracted from PubMed by MedScan application. STRING 8
(Search Tool for the Retrieval of Interacting Genes/Proteins) is a similar tool as IPA that
retrieves protein/gene interactions reported in the literature [104]. Compared with STRING 8,
IPA is more commonly used in industrial sectors, such as pharmaceutical firms because
interactions included in the database are manually curated by scientist from reported literature;
while interactions found in the STRING 8 database include predicted interactions and
interactions resulted from automatic literature-mining searches. On the other hand, STRING 8 is
2

http://www.ariadnegenomics.com/products/pathway-studio/
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freely available and also includes a URL-based programming interface that allows researchers to
query STRING from their applications.
The interactions derived from the computational network model could be confirmed
against databases of known interactions among genes.

A few recognized gene interaction

databases include Kyoto Encyclopedia of Genes and Genomes (KEGG) [105, 106], NCI pathway
interactions database (PID) 3 , and PubMed. The former two databases present gene pathways
maps and molecular networks in diagrams. The latter one, PubMed, is primarily a web-based
portal developed by National Centre for Biotechnology Information (NCBI) at National Library
of Medicine (NLM) of U.S. National Institutes of Health (NIH). It comprises millions of
citations for literature from MEDLINE, life science journals, biomedical journals, and books.
From PubMed, users could view the related literatures on the genes interested and their
respective interactions. From PubMed, users could also be redirected to specific information of
the interactions retrieved from the Gene database under NCBI.

2.5.5 Gene Set Enrichment Analysis
Gene set enrichment analysis (GSEA) allows assessment of gene sets in the genome-wide
expression profiles [107]. Based on the genome-wide gene expression of a set of samples and
their respective phenotype, GSEA would determine how well the members in the gene set
correlated to the phenotypes. Specifically, according to the differential expression between the
two, GSEA maintained a ranked list of genes (L). By going through the ranked list L, a
measurement called enrichment score (ES) would be computed for each gene set using runningsum statistics with weighted correlation of the genes with the phenotype. ES reflects the degree
to which a gene set is overrepresented to both ends of L.

The statistical significance of the

computed ES is indicated by a nominal P-value estimated by randomly permuting the samples
phenotypes. If a gene set is significantly overrepresented with respect to the phenotypes (either
one or both), then it would have extreme ES at both ends of the ranked list L, as shown in Fig.
2.12.

3

http://pid.nci.nih.gov/
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Figure 2.12. An example of enrichment plot for a gene set.

GSEA also allows evaluation of multiple gene sets at once, which is comparing the
enrichment of multiple gene sets against one another in the input genome-wide expression
profiles. This multiple gene sets comparison is actually a multiple comparison problem. In
order to correct the measurements (ES) according to multiple hypotheses testing, the phenotype
labels were randomly permuted. A normalized enrichment score (NES) for each gene set is
generated by averaging enrichment scores from all permutations. Statistical significance of the
NES corresponding to each gene set is indicated by false discovery rate (FDR) in the permutation
analysis by permuting the phenotypes [107]. The gene set that gets high absolute NES and low
FDR compared with other signatures implies that it is more significantly enriched than others in
the provided gene expression profiles.

2.6 Data Used in Experiments
Four sets of published microarray gene expression profiles of lung cancer patients were used
throughout our studies. All four sets of gene expression profiles were quantified with Affymetrix
GeneChip® human genome expression arrays.
The first set is the largest lung cancer microarray data publicly available till date. It
contains gene expression profiles quantified with Affymetrix HG-U133A on 442 lung
adenocarcinoma patient samples obtained from a multi-center microarray study of lung cancer
published by Shedden et al, which also known as the Director’s Challenge Study[2]. This study
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cohort is composed of four data sets (University of Michigan, H. Lee Moffitt Cancer
Center, Memorial Sloan-Kettering Cancer Center, and Dana-Farber Cancer Institute) contributed
by six institutions. The raw microarray data are available from caArray website 4 . The second set
contains 130 adenocarcinoma and squamous cell lung cancer samples published by Raponi et al.
[17]. The third set contains 111 non-small cell lung carcinoma samples published by Bild et al.
[13]. Table 2.3 provides a summary on the data and clinical characteristics of each cohort. The
fourth set contains expressions quantified with Affymetrix HG-U133A on 164 airway epithelial
cells from current and former smokers published by Spira et al. [108]. This cohort is composed
of lung cancer patients and smokers without lung cancer. It was particular used in our study of a
smoking-associate signature and separated into independent training and test sets. Table 2.4
gives a summary of patient characteristics in each set.
Table 2.3. Characteristics summary of three lung cancer patients cohorts.

Affymetrix GeneChip®
Histology
Adenocarcinoma
Squamous cell
Median follow-up (months)
Age (mean, s.d.)
Sex (% male)
Tumor Stage
Stage I
Stage II
Stage III
Stage IV
Unknown

4

Director’s Challenge Study[2]
(n=442)
HG-U133A

Raponi et al. [17]
(n=130)
HG-U133A

Bild et al. [13]
(n=111)
HG-U133 Plus 2

47
64 (10)
50%

100%
34
67 (10)
63%

52%
48%
31
65 (10)
57%

62%
22%
15%
1%

56%
26%
18%
-

60%
16%
22%
2%
-

100%

https://array.nci.nih.gov/caarray/project/details.action?project.id=182
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Table 2.4. Patient characteristics from Spira et al [108].

Age (mean, s.d.)
Sex (% male)
Lung Cancer Histology
Small Cell
Non-small Cell
Unknown
Small Cell Tumor Stage
Limited
Extensive
NSCLC Tumor Stage
Stage I
Stage II
Stage III
Stage IV
Unknown

Training ( n=77)

Test 1 (n=52)

Test 2 (n=35)

57 (14)
78%

55 (16)
75%

64 (11)
69%

15% (6/40)
83% (33/40)
2% (1/40)

25% (5/20)
75% (15/20)
-

17% (3/18)
78% (14/18)
5% (1/18)

3 (3/6)
3 (3/6)

4
1

2
1

30% (10/33)
30% (10/33)
39% (13/33)
-

7% (1/15)
13% (2/15)
47% (7/15)
33% (5/15)
-

14% (2/14)
36% (5/14)
29% (4/14)
21% (3/14)

2.7 Summary
In this chapter, we had reviewed current methods and tools used in gene signature identification
and prognostic prediction using microarray data.

Having studied current approaches and

problems in these methods, we proposed two methodologies to efficiently discover prognostic
gene signatures for lung cancer molecular prognosis.
We first proposed a hybrid system comprised of statistical and machine learning feature
selection methods to identify gene signatures for lung cancer prognosis and chemoresponse
prediction, which will be presented in Chapter 3. From the review of the numerous state-of-theart ranking-based gene selection methods used in microarray studies, each method had their
strengths while other methods missing. Therefore, we hypothesized that through a framework of
a systematic multiple-stage gene filtering approach, we could exploit the strengths from various
methods and lead to identification of predictive biomarkers.
In order to incorporate the interactive machinery of gene functions and signaling pathway
information in biomarker discovery, we proposed the second methodology based on gene
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coexpression networks modeled with implication networks. Implication networks were chosen
over Bayesian networks and ANNs because it could be efficiently constructed and unlike
Bayesian networks, it allows formation of cyclic relations. In Chapter 4, the network-based
approach was studied at the genome-wide scale. Extensive study was carried out to examine the
performance of the network-based approach when it was applied alone or in combination with
feature selection methods. In Chapter 5, the network-based approach was studied on a smaller
pool of genes: the genes that are associated with smoking and lung cancer survival. Chapter 6
evaluates the performance of the implication networks employed in our studies in comparison
with the Boolean implication networks.

Chapter 3
Hybrid Models Identified Gene
Signatures for Lung Cancer Prognosis
and Chemoresponse Prediction
As discussed in Chapter 2, ranking-based methods are simple to be implemented for gene
selection. Statistics methods such as t-test and SAM scale efficiently to large number genes and
control for false positive genes. However, it usually leads to fairly large gene sets (~102).
Feature selection methods such as Relief incorporate the classification in the evaluation of gene
predictive performance. Nonetheless, it’s computationally heavier than statistics methods and
thus does not scale well to the whole genome.
In this chapter, we present our first proposed hybrid system for efficient prognostic gene
signature identification. The proposed hybrid system combined traditional statistics and feature
selection methods in multiple stages to identify predictive gene signatures for lung cancer
prognosis. This system has a few appealing characteristics. The first appealing characteristic is
that it exploits of the strengths of each gene selection methods while avoiding the drawbacks in
the systematic integration.

The second characteristic of the system is that it leads to

identification of small set of genes with high prognostic performance. Smaller size of gene
signatures will not only reduce the time and cost of further validation but also make the clinical
application more feasible.
The proposed hybrid system identified a 12-gene and 15-gen lung cancer prognostic
signatures.

These two signatures are more accurate compared with previously published
42
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signatures in the largest lung adenocarcinoma data samples (n = 442) [2]. Moreover, the 12-gene
signature could identify stage I and stage II patients who might benefit from adjuvant
chemotherapy and who could be spared from it. This implies that the 12-gene signature could be
used to select treatment for stage I and II patients. Quantitative RT-PCR analyses of independent
NSCLC tissue samples confirmed the gene expression patterns of these two signatures.
Functional pathway analysis revealed that the signature genes had interactions with well
established cancer hallmarks, indicating the important roles of the signature genes in tumor
initiation and progression. The 12-gene signature also accurately predicted chemoresistance and
chemosensitivity to Cisplatin, Carboplatin, Paclitaxel (Taxol), Etoposide, Gefitinib and Erlotinib
in a panel of 60 cancer cell lines (NCI-60).
The remainder of this chapter is organized as follows.

Section 3.1 illustrates the

methodology of the proposed hybrid system. The experiment design is presented in Section 3.2.
Section 3.3 describes the identification of various gene signatures using the proposed system.
Survival prediction performance of the identified signatures is presented in Section 3.4 to 3.6.
Section 3.7 presents the survival prediction of early stage patients.

Section 3.8 presents

implications of the 12-gene signature in treatment selection for stage I and II NSCLC. Section
3.9 compares the identified gene signatures with clinical and demographical parameters. Our
gene signatures were compared with published lung cancer signatures in Section 3.10. Section
3.11 confirms the expression patterns of the identified genes.

Section 3.12 shows the

chemoresponse prediction capability provided by the 12-gene signature. Functional pathway of
the 12-gene signature can be found in Section 3.13. The last section, Section 3.14 discusses the
study and concludes the chapter.

3.1 Methodology
We developed a hybrid system with combination of traditional statistics and feature selection
methods for the identification of gene signatures and lung cancer prognosis. As depicted in Fig.
3.1, the proposed system comprised the following steps: 1) Selection a pool of candidate genes
from the whole genome using statistical methods. 2) Ranked the pool of candidate genes with
Relief feature selection. 3) From the top ranked gene, one gene was added at each step to the
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gene set, until the classification accuracy could not be improved by adding one more gene, the
gene set is the prognostic gene signature identified. Specifically, this could be interpreted as a
system with two phases, with statistical methods in the first phase and step-wise forward
selection with feature selection in the second phase.

Expression Profiles of the whole
Genome
Statistical Methods

Pool of Candidate Genes
Relief

Ranked Candidate Genes
From top, add one at a time

Prognostic Classifier

Yes

Accuracy
Increased?
No

Prognostic Gene Signature

Figure 3.1. Hybrid system with traditional raking-based gene selection methods.

This hybrid system utilize the statistical methods in the first phase because statistical
methods is more computational efficient in large scale. Step-wise forward feature selection with
in the second phase allows us to obtain the smallest set of genes with the optimized prognostic
performance.
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3.2 Prognostic Model System
In order to take advantage of different algorithms of gene selection, hybrid models of different
methods in different stages are needed for biomarker discovery and good disease classification.
In this study, we combined statistical methods and machine learning algorithms to identify
prognostic biomarkers of lung adenocarcinoma. The 442 lung adenocarcinoma patient samples
from the Director’s Challenge Study [2] were used in this study. The UM & HLM cohorts from
the sample formed the training set (n = 256), whereas the samples from MSK (n = 104) and the
DFCI (n = 82) formed two independent test sets.
In general, the hybrid systems examined in this study included three phases (Fig 3.2): 1)
identification of a small set of signature genes by combining statistical methods and feature
selection methods from genome-scale transcriptional profiles of the training cohort,

2)

construction of a classifier to predict overall survival in lung cancer patients, and 3) validation of
the gene expression-based prognostic model in two independent patient cohorts. The model
validation and evaluation of the identified gene signature were also compared with over
previously published lung cancer prognostic signatures on the two independent test sets.
Specifically, in the first phase, two combinatorial schemes were studied by joining statistical
methods and feature selection algorithms. The first scheme was combination of pooled-variance
t-test and Relief algorithm. The second scheme was combination of Significance Analysis of
Microarrays (SAM) [34], different-variance t-test, and Relief algorithm. A functional pathway
analysis after the previous two schemes was carried out to explore the biological functions
shared by the gene sets.

Since signatures identified from various approaches performed

differently in different classifiers, Cox model and Naïve Bayes classifiers were used to model the
prognostic model to predict overall survival in lung cancers.
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Figure 3.2. Overview of the hybrid model to molecular prognosis.

3.3 Identification of 15-, 12-, and 16-gene Signature
Three combinatorial schemes with multiple gene selection methods were adopted to examine the
hybrid system for prognostic signatures identification. In the first scheme, t-test was used to
select candidate genes from 22,283 probes quantified on the training cohort (n = 256) in the first
phase. The pooled-variance t-test selected 689 genes with significant differential expression (P <
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0.01) between the low-risk groups (patient who survived longer than 5 years) and high-risk
(those who died within 5 years following surgery) groups. Twenty-seven censored cases with
follow-up time less than 5 years were removed from this analysis due to the uncertainty of
patient post-operative status. In order to refine the gene set into a more feasible size for clinical
application, Relief algorithm implemented in WEKA 3.4 was used to rank each of these 689
genes in terms of the power to separate low-risk and high-risk groups. On the ranked list, stepwise forward selection was used to identify a gene subset with the highest prognostication
accuracy. Specifically, starting from the top ranked gene, one gene was added at each step to the
gene set, until the classification accuracy could not be improved by adding one more gene. At
each step, the gene set was used to classify good-prognosis and poor-prognosis groups with Cox
model, with median risk score of the training set as the cutoff for stratification. On the ranked
list of the 689 genes, the process stopped when the addition of a new gene did not increase the
Cox model stratification after the top 15-gene set. As a result, a 15-gene signature (Table 3.1)
was identified.
In the second scheme, a combination of t-test and SAM was then used to select candidate
prognostic with a predefined false discovery rate. Specifically, a different-variance t-test selected
718 genes with significant differential expression (P < 0.01) between the two prognosis groups.
With false discovery rate (FDR) of 25% (delta = 0.46), SAM selected 1,431 genes that
significantly differentiated the two prognostic groups. There were 583 genes selected by both ttests and SAM, and these were considered the set of candidate prognostic genes for the next
stage of the analysis. In the next step where gene set was further refined, similar approach as
adopted in the first scheme discussed above was employed. Relief algorithm implemented in
WEKA 3.4 was used to rank these 583 genes and forward selection was used to select the most
signature genes starting from the top ranked gene. The gene set was used to classify goodprognosis and poor-prognosis groups with Naïve Bayes algorithm.

The forward selection

process stopped when the addition of a new gene did not increase the classification accuracy as
evaluated in a 10-fold cross validation.

As a result, a 12-gene signature (Table 3.2) was

identified as the most accurate prognostic genes from the set of candidate genes for overall
survival prediction.
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The third approach combined all the steps adopted in the first two approaches with a
biological functional pathway analysis. Specifically, functional pathway analysis was done on
the 15-gene and 12-gene signatures using IPA. By comparing the biological functions of 15- and
12-gene signatures, there were 16 genes sharing the same functions (Table 3.4). As a result, the
16 genes with common functions were selected as the signature gene (Table 3.3).

Table 3.1. List of 15-gene signature.
Probe Set ID
204854_at

Functions

Classification

Collagen biosynthesis, folding, and assembly

Metabolism

206150_at

Gene
GPR162 ///
LEPREL2
CD27

B-cell activation and immunoglobulin synthesis;
signaling transduction

Oncogene

205171_at

PTPN4

Cell growth, differentiation, mitotic cycle, and
oncogenic transformation

Oncogene

201107_s_at

THBS1

Cell-to-cell and cell-to-matrix interactions.

Oncogene

210762_s_at
218340_s_at
211327_x_at
208772_at
211603_s_at
207296_at
214717_at
213779_at
215598_at
201581_at
205308_at

DLC1
UBA6
HFE
ANKHD1
ETV4
ZNF343
DKFZp434H1419
EMID1
TTC12
TXNDC13
FAM164A

A candidate tumor suppressor gene
Ubiquitin-activating protein
Iron absorption
Unknown
Cellular movement
Unknown

Oncogene
Protein Degradation
Signaling Transduction
Structure
Transcription
Transcription

Unknown
Unknown
Binding
Cell redox homeostasis, electron transport chain
Unknown

N/A
N/A
N/A
N/A
N/A
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Table 3.2. List of 12-gene signature.
Probe Set ID
212041_at
222078_at
219808_at

Gene
ATP6V0D1
PKLR
SCLY

Protein Functions

Classification

ATPase
Pyruvate kinase
Catalyzes the decomposition of L-selenocysteine to Lalanine and elemental selenium

Metabolism
Metabolism
Metabolism

209420_s_at
210762_s_at
204524_at
218833_at
208855_s_at

SMPD1
DLC1
PDPK1
ZAK
STK24

Converts sphingomyelin to ceramide
A candidate tumor suppressor gene
Cell signal protein
Cell signal protein
Protein kinase

Metabolism
Oncogene
Oncogene
Oncogene
Signaling Transduction

208775_at

XPO1

Mediates nuclear export of cellular proteins

Signaling Transduction

46142_at

LMF1

Maturation of specific proteins in the endoplasmic
reticulum

Structure

205308_at
221685_s_at

FAM164A
CCDC99

Unknown
Cell cycle

N/A
Signaling Transduction

Table 3.3. List of 16-gene signature.
Probe Set ID

Gene

Functions

Classification

206150_at

CD27

B-cell activation and immunoglobulin synthesis;
signaling transduction

Oncogene

205171_at

PTPN4

Cell growth, differentiation, mitotic cycle, and
oncogenic transformation

Oncogene

201107_s_at

THBS1

Cell-to-cell and cell-to-matrix interactions.

Oncogene

211327_x_at
211603_s_at
201581_at
212041_at
222078_at
219808_at

HFE
ETV4
TXNDC13
ATP6V0D1
PKLR
SCLY

Signaling Transduction
Transcription
N/A
Metabolism
Metabolism
Metabolism

209420_s_at
210762_s_at
204524_at
218833_at
208855_s_at
208775_at
46142_at

SMPD1
DLC1
PDPK1
ZAK
STK24
XPO1
LMF1

Iron absorption
Cellular movement
Cell redox homeostasis, electron transport chain
Atpase
Pyruvate kinase
Catalyzes the decomposition of L-selenocysteine
to L-alanine and elemental selenium
Converts sphingomyelin to ceramide
A candidate tumor suppressor gene
Cell signal protein
Cell signal protein
Protein kinase
Nuclear protein transport
Maturation of specific proteins in the endoplasmic
reticulum

Metabolism
Oncogene
Oncogene
Oncogene
Signaling Transduction
Signaling Transduction
Structure
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Table 3.4. Comparison of biological functions between the 12- and 15-gene signatures with curated
database.
Category

Category
Cancer
Cardiovascular Disease
Connective Tissue Disorders
Dermatological Diseases and Conditions
Genetic Disorder
Hematological Disease
Hepatic System Disease

Diseases and
Disorders

Immunological Disease
Infection Mechanism
Inflammatory Disease
Inflammatory Response
Metabolic Disease
Neurological Disease
Reproductive System Disease
Respiratory Disease
Skeletal and Muscular Disorders
Amino Acid Metabolism
Antigen Presentation
Carbohydrate Metabolism
Cell Cycle
Cell Death
Cell Morphology
Cell Signaling
Cell-To-Cell Signaling and Interaction
Cellular Assembly and Organization

Molecular and
Cellular
Functions

Cellular Compromise
Cellular Development
Cellular Function and Maintenance
Cellular Growth and Proliferation
Cellular Movement
DNA Replication, Recombination, and Repair
Drug Metabolism
Gene Expression
Lipid Metabolism
Molecular Transport
Nucleic Acid Metabolism
Post-Translational Modification

12-gene

15-gene

Common
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Protein Synthesis
Protein Trafficking
RNA Trafficking
Small Molecule Biochemistry
Cardiovascular System Development and Function
Cell-mediated Immune Response
Hematological System Development and Function
Physiological
System
Development
and Function

Immune Cell Trafficking
Nervous System Development and Function
Organ Development
Skeletal and Muscular System Development and
Function
Tissue Development
Tumor Morphology
Visual System Development and Function

3.4 Survival Prediction Using 15-gene Prognostic Model
Using expression profiles of the 15 genes as predictors, a prognostic classifier was constructed to
stratify patients into low- and high-risk of failure in survival (i.e. death) using a multivariate Cox
proportional hazard model. The Cox model of overall survival was constructed based on the 15gene signature, with each gene variable as a covariate. In the UM & HLM training samples (n =
256), a survival risk score was generated for every patient, with a higher risk score representing a
greater probability of death. From the gene expression-defined risk scores in the training cohort,
median of the risk score (value of -1.79) was identified as the cut-off to stratify patients into lowand high-risk groups. The constructed training model and the cut-off value were then applied to
the two validation sets. In all three patient cohorts, the 15-gene defined model stratified patients
into prognostic groups with distinct overall survival (log-rank P < 0.03; Fig. 3.3)
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Figure 3.3. Kaplan-Meier analysis of the 15-gene signature on patients on all stages.

3.5 Survival Prediction Using 12-gene Prognostic Model
To predict overall survival using the 12-gene signatures, expression profiles of the identified 12
genes were used as predictors in a prognostic classifier to stratify patients into low-risk (5-year
survival) and high-risk (non-5-year survival) groups. The Naïve Bayes classifier implemented in
WEKA 3.4 was used in the classification on UM & HLM training samples (low-risk n = 104;
high-risk n = 125). Twenty-seven censored cases without sufficient follow-up information were
removed in the model construction. Priors estimated by the model are 0.45 for low-risk class and
0.55 for high-risk class. Other parameters of the trained Naïve Bayes model, including the mean
and standard deviation for each of the 12 genes in both low- and high-risk groups, are listed in
Table 3.5.
Table 3.5. Parameters estimated in the 12-gene Naive Bayes classifier.

Gene (attribute)

LMF1
DLC1
PKLR
ATP6V0D1
CCDC99
SCLY
PDPK1
FAM164A
SMPD1
XPO1
ZAK
STK24

Low-risk
mean ( μ Li )

Low-risk
standard
deviation ( σ Li )

High-risk
mean ( μ Hi )

High-risk
standard
deviation ( σ Hi )

101.6708
868.5886
14.3474
1388.054
277.1923
58.3824
297.6373
264.8707
278.5686
1674.3741
132.694
2248.6647

31.6461
578.3862
6.872
398.6874
56.2284
13.2988
117.3514
106.5128
84.5316
344.9824
67.7063
529.6098

88.6869
648.4284
11.002
1209.6369
300.0086
63.6222
253.7384
223.8295
239.3571
1824.6274
159.0546
2457.9982

29.5986
530.6969
5.5501
325.7233
60.678
13.7703
103.0455
96.6066
65.4393
400.4278
79.1456
576.496
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The Naïve Bayes classifier computes the posterior probability of death within 5 years
after surgery in each patient. This posterior probability represents the risk for tumor recurrence in
patients, since recurrence is the major cause of treatment failure (i.e. death) in lung cancer.
Based on the posterior probability, a patient is classified into the high-risk group if the value is
greater than 0.5; or into the low-risk group otherwise. The training model was evaluated in a 10fold cross validation. Without parameter re-estimation, this model was then used to predict
posterior probability representing the risk for tumor recurrence in each patient in two test sets
(MSK and DFCI), as well as the censored cases left out of the model construction. The
distribution of the posterior probability of 442 patients in this study was illustrated in Fig. 3.4A.
After obtaining the predicted outcomes, Kaplan-Meier (KM) analysis was carried out to estimate
the average survival probability at the 5-year mark following surgery. Results show that highrisk posteriors from the prognostic model are strongly associated with the 5-year survival
probabilities (Fig. 3.4B). Patients with a high probability of tumor recurrence tend to be more
likely to have treatment failure after surgery.

This indicates that the high-risk posterior

probability computed by the model is a good prognostic factor of lung cancer survival. The wide
95% confidence interval at posteriors ranging from 0.35 to 0.6 (Fig. 3.4B) might be due to the
small sample size in this distribution (Fig. 3.4A). Furthermore, a posterior of 0.5 means that the
chance of tumor recurrence is random, which also leads to a looser confidence interval.
Using the prognostic categorization scheme described above, the 12-gene signature
separated patients into high- and low-risk groups with significantly distinct (log-rank P = 6.96e7) post-operative survival on the training cohort in Kaplan-Meier analysis (Fig. 3.5A). This
scheme generated significant patient stratification on independent validation sets MSK (log-rank
P = 9.88e-4; Fig. 3.5B) and DFCI (log-rank P = 2.57e-4; Fig. 3.5C).
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Figure 3.4. Association of the 12-gene risk score algorithm and lung cancer survival. (A) Histogram
showing the distribution of the risk scores (posterior probabilities of high-risk) in the whole studied
cohort. (B) Average rate of death at five years after surgery corresponding to 12-gene risk score (posterior
probability). The dotted lines represent 95% confidence interval.

Figure 3.5. Kaplan-Meier analysis of the 12-gene prognostic classification in lung cancer patients.

3.6 Survival Prediction Using 16-gene Prognostic Model
A prognostic classifier was constructed using the expressions of the 16-gene signature to stratify
patients into low- and high-risk of death using a multivariate Cox proportional hazard model
with a similar approach adopted for 15-gene prognostic model.

With the 16 genes as a

covariates, a survival risk score was generated for patients in the UM & HLM training samples
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(n = 256). From the distribution of gene expression-defined risk scores in the training cohort, the
3rd quartile (value of -1.5724) was identified as the cut-off to stratify patients into low- and highrisk groups. Then, the constructed training model and the cut-off value were applied to the two
validation sets. In all three patient cohorts, the 16-gene prognostic model stratified patients into
prognostic groups with distinct overall survival (log-rank P < 0.03; Fig. 3.6)

Figure 3.6. Prognostic performance of the 16-gene signature in patients on all stages.

3.7 Survival Prediction for Stage I NSCLC Patients
In current practice, treatment for patients diagnosed with NSCLC is based on AJCC tumor stage.
Surgical resection to remove the tumor is the major treatment option for stage I NSCLC patients.
However, about 35-50% of stage I NSCLC patients will develop and die from tumor recurrence
within the five years following surgery [4, 5]. On the other hand, stage IB patients who received
surgical resection followed by adjuvant chemotherapy showed improved survival rate [30].
Thus, we sought to explore whether the 15-, 12-, and 16-gene expression-defined prognostic
classifier could identify specific high-risk patients with stage I tumors for the aggressive
adjuvant chemotherapy.
Results show that the 15-gene prognostic signature could identify high-risk patients with
stage I tumors on training cohort (results not shown) and DFCI test cohort (log-rank P = 0.02;
Fig 3.7B) but not on the MSK Stage I patients (log-rank P = 0.12; Fig 3.7A) and the stage IA
patients in the combined cohort of MSK and DFCI (results not shown). The 15-gene prognostic
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model could also separate high- and low-risk groups (log-rank P = 0.008) within stage IB
patients in the combined test sets (Fig. 3.7C).

Figure 3.7. Prognostic performance of the 15-gene signature in stage I patients.

The 16-gene prognostic signature performed similarly as the 15-gene model in stage I
patients. The 16-gene prognostic model generated significant stratifications in patients with
stage I tumors on training cohort (results not shown) and DFCI test cohort (log-rank P = 0.01;
Fig 3.8B), but not on the MSK test cohort (log-rank P = 0.34; Fig 3.8A) and the stage IA patients
in the combined test cohort (result not shown). The 16-gene prognostic model also separated
high- and low-risk groups (log-rank P = 0.02) within stage IB patients in the combined test sets
(Fig. 3.8C).

Figure 3.8. Prognostic performance of the 16-gene signature in stage I patients.
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The 12-gene prognostic signature could reliably identify high-risk patients with stage I
tumors on both the training cohort (results not shown) and two independent test cohorts (log-rank
P = 0.04; Fig. 3.9A, Fig. 3.9B). The prognostic model also separated high- and low-risk groups
(log-rank P = 4.73e-3) within stage IB patients in the combined test sets (Fig. 3.9C).

Figure 3.9. Prognostic performance of the 12-gene signature in stage I patients.

These results demonstrate that the identified 12-gene signature is independent of the
current AJCC staging system. Result from the KM analyses that the 12-gene signature could
stratify Stage I patients into two significantly distinct survival groups demonstrate that the 12gene signature provides more precise prognosis than the current AJCC staging system. Using the
12-gene model, stage I NSCLC patients could be advised to receive adjuvant chemotherapy
according to the expression profiles of the 12 signature genes.

3.8 Treatment Selection for Stage I and II NSCLC Patients
with the 12-gene Signature
Among the three prognostic models constructed, 12-gene prognostic model was the only model
that generated significant stratification on the stage I patients in both the training cohort (results
not shown) as well as two test cohorts (Fig 3.10). Therefore, we further assessed whether the 12gene signature could be used for treatment selection for stage I and II NSCLC patients. Patients
who did not receive chemotherapy were selected for this analysis. Results from the KM analysis
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show that the prognostic model separated high- and low-risk stage I patients without
chemotherapy in the training (UM & HLM; log-rank P = 0.04; Fig. 3.10A) and test cohorts
(MSK & DFCI; log-rank P = 0.02; Fig. 3.10B). Similarly, the model differentiated high- and
low-risk stage II patients without chemotherapy in the training (log-rank P = 0.06; Fig. 3.10C)
and test cohorts (log-rank P = 0.03; Fig. 3.10D) in KM analyses. These results indicate that the
12-gene expression-defined prognostic model could reliably select patients with early stage
NSCLC for adjuvant chemotherapy. Meanwhile, it could also spare some low-risk stage I and II
NSCLC patients from chemotherapy based on the expression patterns of the identified gene
markers in the tumors.

Figure 3.10. Evaluation of the 12-gene signature in treatment selection.
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3.9 Prognosis Evaluation of the Identified Signature with
Clinical Covariates
To confirm the prognostic power of the identified signatures, the expression-defined prognostic
model was evaluated with commonly used prognostic factors of lung cancer, including gender,
age, and tumor stage on the combined testing cohorts (DFCI and MSK).
The posterior probability of high-risk estimated by the 12-gene Naïve Bayes classifier,
termed as 12-gene risk score, was used as a covariate in the multivariate Cox analysis. Risk
scores estimated by the 15-gene and 16-gene fitted Cox model was used as a covariate in the
analysis (Table 3.6). Results showed that without the 12-, 15-, or the 16-gene risk score, tumor
stage was the only factor significantly (P < 0.00006) associated with risk of lung cancer death.
When the 12-gene risk score was added to the multivariate Cox model, the 12-gene risk score
demonstrated a strong association with the lung cancer survival (hazard ratio = 3.94, 95% CI:
[2.07, 7.52]), and tumor stage remained significant (Table 3.6). When the 15-gene risk score
was added to the multivariate Cox model, tumor stage remained significant and the 15-gene risk
score also showed significantly association with the lung cancer survival (hazard ratio = 1.99,
95% CI: [1.37,2.89]; Table 3.6). In the analysis with the 16-gene risk score, the 16-gene risk
score also appeared to be a significant factor associated with the lung cancer survival (hazard
ratio = 2.50, 95% CI: [1.33,3.59]) and tumor stage remained significant (Table 3.6).
A comprehensive evaluation was carried out with all available clinical covariates and
demographic factors in the dataset, including smoking history, race, and tumor differentiation
(Table 4). In this comprehensive evaluation, the 12-gene risk score remained as a highly
significant prognostic factor with a hazard ratio of 4.19 (95% CI: [2.08, 8.46]; Table 3.7). The
risk scores of the 15- and 16-gene demonstrated to be significant factors in this analysis while
comparing with all clinical and demographic factors, with a hazard ratio of 1.81 (95% CI: [1.23,
2.65]) and 2.45 (95% CI: [1.72, 3.50]) respectively (Table 3.7).
In both multivariate analyses, the hazard ratios of the 12-gene risk score algorithm were
higher than other clinical covariates except tumor stage (III vs. I), while there is no significant
difference between the hazard ratio of the 12-gene signature and tumor stage. Hazard ratio of the
15-gene risk score was comparatively good as the hazard ratio of the tumor stage (III vs. I) in the
first analysis with major clinical covariates. However, in the comprehensive analysis, the hazard

3. Hybrid Models Identified Gene Signatures for Lung Cancer Prognosis and
Chemoresponse Prediction

60

ratio of tumor stage (III vs. I) was significantly higher than the hazard ratio of 15-gene risk score.
The hazard ratio of the 16-gene risk score was comparatively good as the hazard ratio of tumor
stage with stage II vs. I but not significantly higher than the hazard ratio of tumor stage III vs. I
in both multivariate analyses. These results demonstrate that the 12-gene signature is a more
accurate prognostic factor than some commonly used clinical parameters.
Table 3.6. Multivariate Cox proportional analysis of the 12-, 15-, and 16-gene risk score and major
clinical covariate including gender, age, and tumor stage on testing cohorts (MSK and DFCI).
Variable*
P-value
Hazard Ratio (95% CI) ψ
Analysis without gene signature risk score
Gender (Male)
0.22
1.34 (0.84-2.16)
Age at diagnosis (>60)
0.08
1.61 (0.95-2.74)
Cancer Stage
Stage II
6.25E-05
2.91 (1.72-4.91)
Stage III
1.09E-05
4.16 (2.20-7.85)
Analysis with 12-gene risk score
Gender (Male)
0.17
1.40 (0.87-2.26)
Age at diagnosis (> 60)
0.29
1.34 (0.78-2.31)
Cancer Stage
Stage II
3.47E-04
2.61 (1.54-4.43)
Stage III
7.40E-06
4.31 (2.28-8.16)
12-gene risk score
3.10E-05
3.94 (2.07-7.52)
Analysis with 15-gene risk score
Gender (Male)
0.20
1.36 (0.85-2.18)
Age at diagnosis (> 60)
0.08
1.60 (0.94-2.74)
Cancer Stage
Stage II
1.32E-04
2.80 (1.65-4.74)
Stage III
4.82E-05
3.73 (1.98-7.05)
15-gene risk score
2.84E-04
1.99 (1.37-2.89)
Analysis with 16-gene risk score
Gender (Male)
0.11
1.49 (0.92-2.41)
Age at diagnosis (> 60)
0.18
1.44 (0.84-2.48)
Cancer Stage
Stage II
5.36E-05
2.97 (1.75-5.03)
Stage III
7.52E-07
5.19 (2.70-9.96)
16-gene risk score
6.24E-07
2.50 (1.33-3.59)
*Gender was binary variable (0 for female and 1 for male); age at diagnosis was a binary variable (0 for < 60 years
old and 1 otherwise); tumor stage was categorical variable of 3 categories (Stage I [as the reference group], Stage II,
and Stage III). Risk score was continuous variable; where hazard ratio describes the relative risk between the mean
risk scores of high-risk and low-risk groups. ψ denotes confidence interval.
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Table 3.7. Multivariate Cox proportional analysis of all available clinical covariates and 12-, 15-,
and 16-gene risk score on testing cohorts (DFCI and MSK).
Variable*
P-value
Hazard Ratio (95% CI)ψ
Analysis without 12-gene risk score
Gender (Male)
0.43
1.22 (0.74-1.99)
Age at diagnosis (>60)
0.05
1.70 (0.99-2.92)
Race
Others/Unknown
0.28
0.43 (0.09-1.97)
White
0.10
0.28 (0.06-1.28)
Tumor differentiation
Moderately differentiated
0.14
0.53 (0.23-1.24)
Poorly differentiated
0.70
1.17 (0.53-2.61)
Smoking history
Smokers
0.62
0.84 (0.43-1.66)
Unknown
0.91
0.89 (0.11-7.10)
Cancer Stage
3.31E-04
2.72 (1.57-4.69)
Stage II
2.38E-05
4.93 (2.35-10.33)
Stage III
0.43
1.22 (0.74-1.99)
Analysis with 12-gene risk score
Gender (Male)
0.38
1.25 (0.76-2.08)
Age at diagnosis (>60)
0.12
1.56 (0.89-2.72)
Race
Others/ Unknown
0.52
0.60 (0.13-2.77)
White
0.11
0.29 (0.07-1.32)
Tumor differentiation
Moderately differentiated
0.17
0.56 (0.24-1.29)
Poorly differentiated
0.83
0.91 (0.41-2.06)
Smoking history
Smokers
0.61
0.84 (0.43-1.64)
Unknown
0.79
0.75 (0.09-5.98)
Cancer Stage
Stage II
1.37E-03
2.44 (1.41-4.22)
Stage III
5.12E-06
5.88 (2.75-12.58)
12-gene risk score
6.34E-05
4.19 (2.08-8.46)
Analysis with 15-gene risk score
Gender (Male)
0.36
1.26 (0.77-2.06)
Age at diagnosis (>60)
0.04
1.75 (1.02-3.01)
Race
Others/ Unknown
0.38
0.50 (0.11-2.31)
White
0.14
0.32 (0.07-1.45)
Tumor differentiation
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Poorly differentiated
Smoking history
Smokers
Unknown
Cancer Stage
Stage II
Stage III
15-gene risk score
Analysis with 16-gene risk score
Gender (Male)
Age at diagnosis (>60)
Race
Others/ Unknown
White
Tumor differentiation
Moderately differentiated
Poorly differentiated
Smoking history
Smokers
Unknown
Cancer Stage
Stage II
Stage III
16-gene risk score

0.16
0.99

0.55 (0.24-1.27)
0.99 (0.44-2.23)

0.93
0.85

0.97 (0.49-1.91)
1.22 (0.15-9.89)

2.61E-04
5.19E-05
2.47E-03

2.76 (1.60-4.77)
4.66 (2.21-9.82)
1.81 (1.23-2.65)

0.17
0.09

1.42 (0.86-2.35)
1.63 (0.93-2.85)

0.22
0.05

0.38 (0.08-1.77)
0.22 (0.05-1.00)

0.16
0.96

0.55 (0.23-1.28)
1.02 (0.45-2.30)

0.53
0.96

0.81 (0.41-1.59)
0.94 (0.12-7.54)

2.37E-04
2.09E-06
7.49E-07
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2.79 (1.62-4.83)
6.34 (2.96-13.58)
2.45 (1.72-3.50)

* Gender was binary variable (0 for female and 1 for male); age at diagnosis was a binary variable (0 for < 60 years
old and 1 otherwise); race was a categorical variable of 3 categories (African American [as the reference group],
White, and Others [composed of Asian (5) , Hawaiian or Pacific Islander (1), and unknown]); tumor grade was
categorical variable of 3 categories (Well [as the reference group], Moderately, and Poorly differentiate); Smoking
history was a categorical variable of 3 categories (Non-smokers, Smokers, and Unknown); tumor stage was
categorical variable of 3 categories (Stage I [as the reference group], Stage II, and Stage III). Risk score was
continuous variable; where hazard ratio describes the relative risk between the mean risk scores of high-risk and
low-risk groups.
ψ
denotes confidence interval.

3.10 Comparison with other Lung Cancer Gene Signatures
In the Director’s Challenge study [2], prognostic classifiers were constructed with gene
expression signatures alone or gene expression signatures combined with clinical covariates.
Among twelve gene signatures analyzed in their study (Table A.1), the best signature was
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reported as “method A” (referred to as “Shedden A” in this study), which contains about 9,591
genes/probes. In order to compare the predictive performance of our prognostic models with
their best model, the estimated hazard ratio and the concordance probability estimate (CPE) of
the models were evaluated.

Hazard ratios greater than 1 indicate that patients with high

predicted risk scores have poor clinical outcome. CPE value close to 1 indicates that the model
has strong predictive; the model has poor predictive power (comparable to random prediction)
when the CPE value close to 0.5.
Results show that the proposed 12-gene signature has the highest hazard ratio and CPE in
both test sets when compared to the gene signatures from Director’s Challenge Study [2] (Fig.
3.11A, 3.11B). Although the hazard ratios of the 15-gene signature in both test sets were slightly
lower than the 12-gene, there was no significant difference between the two signatures.
Comparatively, the 16-gene signature didn’t perform as well as the 12- and 15-gene signature
because the hazard ratio was not significant in MSK test cohort (Fig 3.11A). In patient cohorts
with stage I tumors only, the three identified signatures had comparative performance as the
“method A” because each signature was able to generate significant hazard ratio in only one of
the two test cohort (Fig. 3.11C).
Among the three signatures presented thus far, the 12-gene signature gave the best
performance. Therefore, we further compared the 12-gene signature with other published lung
cancer signatures. To evaluate the 12-gene signature with previously published 14 lung cancer
signatures [2, 11, 12, 15-17, 29, 30, 109, 110] (Table A.2), Gene Set Enrichment Analysis
(GSEA 5 ) was used to assess the enrichment of these signatures on 5-year survival. The
normalized enrichment score (NES) and its corresponding false discovery rate (FDR) associated
with each gene signature were evaluated on all 442 samples used in this study. In general, a gene
set with high NES and low FDR is desired, as it indicates that the gene set expresses diversely
with respect to the clinical outcome and the finding is unlikely to be by chance. In comparison
to 14 other published gene signatures, the 12-gene signature exhibits high enrichment in groups
of patients survived 5 year or longer with significantly low FDR (absolute NES = 1.5; FDR <
0.10) (Fig. 3.12). In this analysis, the most enriched signature with the lowest FDR was
SHEDDEN_MH of 244 genes (absolute NES = 2.00; FDR < 0.002). Overall, among the 15 gene
5

http://broad.harvard.edu/gsea/
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sets studied, the 12-gene signature is one of the best lung cancer signatures evaluated with
GSEA.
(A)

(B)

(C)

(D)

Figure 3.11. Evaluation of the 15-, 12-, and 16-gene prognostic models with molecular prognostic
models presented by Shedden et al. [2]. Hazard ratio (A, C) and concordance probability estimate
(CPE) (B, D) were compared on patients in all stages (A, B) and stage I (C, D) of lung cancer. Error bars
in (A) and (C) represent 95% confidence interval of hazard ratio.
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Figure 3.12. Gene set enrichment analysis of the 12-gene signature along with 14 published gene
signatures for NSCLC.

3.11 RT-PCR Validation of Gene Expression Patterns
In order to further confirm the expression patterns of the 25 genes from the three signatures
identified, RT-PCR microfluidic low density arrays were used to analyze independent NSCLC
tumor samples. 91 NSCLC specimens obtained from West Virginia University Tissue Bank and
the Cooperative Human Tissue Network (CHTN) (Ohio State University Tissue Bank,
Columbus, OH) were analyzed.
First, the gene expression patterns for the 25 genes obtained from both microarray and
RT-PCR were compared in terms of lymph node metastasis (Fig. 3.13A). On the RT-PCR data
normalized with POLR2A, gene expression fold changes of the 25 genes in lymph node positive
(LN+) versus lymph node negative (LN-) samples were compared with those in microarray data
from Director’s Challenge study [2]. The results show that the expression patterns of the 25
genes measured in both platforms are concordant in terms of lymph node metastasis.
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Figure 3.13. Comparison of gene expression patterns of the 25 signature genes measured with DNA
microarray and RT-PCR microfluidic low density arrays (LDA). Gene expression fold change in
lymph node positive (LN+) patients vs. lymph node negative (LN-) patients was compared (A). Samples
included in the fold change comparison are summarized in (B).

3.12 Prediction of Chemoresponse in NCI-60 Cell Lines
After demonstrating the promising performance of the 12-gene signature in predicting lung
adenocarcinoma overall survival, we sought to explore whether the signature can predict
chemoresponse to anti-lung cancer agents, including Cisplatin, Carboplatin, Paclitaxel,
Etoposide, Erlotinib, and Gefitinib.
In this analysis, transcriptional gene expression profiles and activity profiles of various
drugs used in chemotherapy in the NCI-60 cell lines [111] were used. The transcriptional gene
expression profiles in all the 60 cell lines included in the study retrieved with CellMiner 6 . The
data retrieved were generated on Affymetrix U133A and normalized using the GCRMA method
6

http://discover.nci.nih.gov/cellminer
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[112]. The drug activity profiles, measure in log10 (GI50), were retrieved from Developmental
Therapeutic Program at NCI/NIH through DTP Data Search 7 . The latest screening results for
each studied drug were used in the analysis. The drug activity data was further processed to
define drug resistance and sensitivity. Specifically, for each drug, log10(GI50) values were first
normalized across the 60 cell lines. Cell lines with log10(GI50) at least 0.5 standard deviations
(SDs) above the mean were defined as resistant to the drug. Those with log10(GI50) at least 0.5
SDs below the mean were defined as sensitive to the drug. The remaining cell lines with
log10(GI50) within 0.5 SDs were defined as intermediate [113, 114].
For each drug, cancer cell lines that are either sensitive or resistant to the drug were
included to build a chemoresponse classifier based on the 12-gene expression profiles in the cell
lines. The performance of the classifiers was evaluated with leave-one-out cross validation
(Table 3.8). Statistical significance of the classification was evaluated by comparing the overall
accuracy of the 12-gene signature with that of 1000 random signatures of the same size using the
same algorithm. Result show that the overall prediction accuracy of chemoresponse was 81% (P
< 0.004) for Paclitaxel (Taxol), 78% (P < 0.001) for Carboplatin, 80% (P < 0.005) for Cisplatin,
73% (P < 0.017) for Etoposide, 79% (P < 0.001) for Erlotinib, and 94% (P < 0.001) for
Gefitinib. These results demonstrate that the 12-gene signature accurately predicted sensitivity
and resistance to common lung cancer chemotherapeutic agents in cancer cell lines.
Table 3.8. Prediction accuracy of chemoresponse in NCI-60 cell lines using the 12-gene signature.
Drug
Carboplatin
Paclitaxel
Cisplatin
Etoposide
Erlotinib
Gefitinib

Sensitivity
(chemoresistance)
76% (19/25)
72% (8/11)
85% (22/26)
80% (16/20)
79% (11/14)
92% (11/12)

Specificity
(chemosensitivity)
80% (16/20)
87% (13/15)
74% (14/19)
67% (14/21)
80% (16/20)
95% (20/21)

Overall accuracy

78% (35/45)
81% (21/26)
80% (36/45)
73% (30/41)
79% (27/34)
94% (31/33)

P-value*

< 0.001
0.004
0.005
0.017
0.001
< 0.001

* A P-value < 0.05 represents that the overall accuracy of the 12-gene signature is significantly higher than that of
random gene signatures with the same size using the same classifier in 1000 tests

7

http://dtp.nci.nih.gov/dtpstandard/dwindex/index.jsp
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The differential expression in sensitive and resistant lung cancer cell lines was also
analyzed for each signature gene. The drug responses of the lung cancer cell lines in the NCI-60
panel were provided in Table 3.9.
Among the signature genes, the over-expression of STK24 was linked to chemoresistance
to all the studied drugs except Gefitinib in the lung cancer cell lines; whereas the over-expression
of FAM14A was associated with chemosensitivity to all the studied drugs except Gefitinib in
lung cancer cell lines. The under-expression of STK24 was associated with resistance to Gefitinib
(P < 0.05). The under-expression of CCDC99 was observed in resistance to Paclitaxel (P <
0.05). The over-expression of DLC1 was associated with chemoresistance to Erlotinib (P <
0.05), Paclitaxel, and Cisplatin; whereas its under-expression was associated with
chemoresistance to Etoposide and Carboplatin (not statistically significant) (Fig. 3.14).

Figure 3.14. Genes with at least 1.5-fold expression fold change in resistant vs. sensitive lung cancer
cell lines to six anticancer drugs. In the graph, differential expression with statistical significance (P <
0.05, t-tests) is marked by a red asterisk.
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Table 3.9. Machine learning algorithm and genes used in chemoresponse prediction using 12-gene
signature.
Anti-cancer
Agent

Machine learning
algorithm

Carboplatin

RBF Network (seed
= 2)

ATP6V0D1
CCDC99
FAM164A
LMF1
PDPK1
PKLR
SCLY
SMPD1
STK24
XPO1

LC:EKVX
LC:NCI_H322M

LC:NCI_H460
LC:NCI_H522
(LC:NCI_H23 not
included due to
missing values)

Paclitaxel

IBK (k=3)

CCDC99
DLC1
LMF1
PKLR
SMPD1
XPO1
ZAK

LC:HOP_92
LC_EKVX

LC:NCI_H460
LC:NCI_H522

Cisplatin

Decorate (PART as
base learner)

ATP6V0D1
CCDC99
FAM164A
LMF1

LC:NCI_H226
LC:EKVX
LC:NCI_H322M

LC:HOP_62
LC:NCI_H460
(LC:NCI_H23 not
included due to
missing values)

Etoposide

AdaBoostM1 (seed
= 2, Random Tree as
base learner)

CCDC99
LMF1
SCLY
STK24
XPO1

LC:EKVX
LC:NCI_H322M

LC:HOP_62
LC:NIC_H460

Erlotinib

RBF Network

DLC1
LMF1
XPO1
SMPD1
STK24
PDPK1
ZAK
PKLR
CCDC99

LC:NCI_H226
(LC:NCI_H23 not
included due to
missing values)

LC:EKVX
LC:NCI_H322M
LC:NCI_H522

Genes Selected

Resistant lung
cancer cell lines

Sensitive lung
cancer cell lines
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Multilayer
Perceptron (seed=2,
learning rate=0.4)

ATP6V0D1
SMPD1
XPO1
PKLR
STK24
SCLY

LC:A549
LC:HOP_62
LC:HOP_92
LC:NCI_H226
(LC:NCI_H23 not
included due to
missing values)
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LC:EKVX
LC:NCI_H322M

3.13 Functional Pathway Analysis of 12-gene Signature
Having established the clinical relevance of the 12-gene prognostic signature, we sought to
explore the functional involvement of this gene set in lung tumorigenesis and tumor progression.
Two functional pathway analysis tools, Ingenuity Pathway Analysis (IPA) and Pathway Studio
7.0, were used to obtain molecular interaction related to the 12 genes reported in literature.
Results from IPA show that the signature genes interact with major cancer signaling pathways,
such as TNF and AKT (Fig. 3.15A). In the study with Pathway Studio 7.0, interactions among the
12 genes and 13 major lung cancer hallmarks (EGF, EGFR, KRAS, MET, RB1, TP53, E2F1,
E2F2, E2F3, E2F4, E2F5, AKT1, and TNF) reported in the literature were explored. Results
from Pathway Studio revealed various types of interactions ranging from regulation to protein
modification among the 12 genes and eight out of 13 cancer hallmarks (Fig. 3.15B). Results
from both functional pathway analyses suggest that the 12 signature genes are involved in lung
cancer oncogenesis and tumor progression.
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Figure 3.15. Functional pathway analysis of the 12 signature genes. (A) Using core analysis from
Ingenuity Pathway Analysis (IPA), curated interactions were revealed among the identified signature
genes and major lung cancer signaling pathways. (B) Six of the 12 genes also exhibited various curated
interactions with eight prominent lung cancer hallmarks with Pathway Studio 7.0.

3.14 Conclusions and Discussions
Gene signatures are essential for the development of personalized medicine for precise lung
cancer prognosis.

With the availability of genome-wide profiles in the post-genomic era,

innovative computational models are needed to identify clinically important gene markers.
Given the current scale of high throughput data with thousands of genes, traditional methods for
gene selections would not be adequate. Instead, a hybrid system with combinatorial gene
selection scheme of different gene filtering methods at different stages is needed. This study
presents a hybrid model system for the identification of gene signatures for lung cancer
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prognosis. The hybrid model systems identified three signatures: a 15-gene, a 12-gene, and a 16gene signature.
In the hybrid model, SAM and t-tests was used to identify candidate genes showing
differential expression between two prognostic groups in the training set. SAM controls for
multiple testing problem and is very similar to t-test. We used t-tests (P < 0.01) to select genes
with certain level of differential expression between two prognostic groups, and used SAM to
control for false discovery rate (FDR< 25%). The results from SAM and t-test are not exactly the
same, because the SAM method adds a constant (s) in the denominator to ensure that genes with
a very small variance in the samples and a small differential expression are not selected as
significant markers. When s=0, SAM is exactly the same as t-test [34]. This hybrid system was
able to identify a small set of genes that are more accurate than previously published lung cancer
gene signatures on the same datasets. We have experimented to stringent the threshold in SAM
statistics. As a result, there were 87 genes with a FDR <10% and no genes were selected with a
FDR < 1% from the training set. The 87 genes were not able to generate significant stratification
in all three patient cohorts. These results indicate that using SAM method alone is not sufficient
to identify the most accurate prognostic gene signature.
Among the 12- and 15-gene signatures identified using t-tests, SAM, and Relief, 16 genes
share common biological functions (Table 3.3). The performance of these gene signatures is
comparable to one another in term of Kaplan-Meier analyses, hazard ratio of the prognostic
model, and multivariate analyses with clinical covariate and demographic factors. When 3-year
survival was used to define high- and low-risk groups (high-risk: death within 3-y; low-risk:
alive after 3-y), the 12-gene risk algorithm achieved a sensitivity (correctly predicted high-risk
patients) of 73.65% in the training set, 86.96% in MSK, and 68.18% in DFCI, and a specificity
(correctly predicted low-risk patients) of 59.21% in the training set, 57.75% in MSK, and
76.36% in DFCI (Table 3.10). The sensitivity and specificity of the 15-gene signature in
predicting 3-year survival was also similar as the 12-gene signature, with sensitivity of 76.84%,
82.61%, 86.36% and specificity of 64.47%, 50.70%, 47.27% in training, MSK, and DFCI
respectively.

Compared to 12- and 15-gene signature, the 16-gene signature gave lower

sensitivity but higher specificity (Table 3.10).
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Table 3.10. Sensitivity and specificity of the 12-, 15- and 16-gene prognostic models.
Sensitivity (% of correctly
predicted high-risk patients)

Specificity (% of correctly
predicted low-risk patients)

n
12-gene 15-gene 16-gene
n
12-gene 15-gene 16-gene
3-year survival as the cutoff (high-risk: death within 3-y; low-risk: alive after 3-y)
95
73.65
76.84
47.37
152
59.21
64.47
87.50
UM & HLM
23
86.96
82.61
60.87
71
57.75
50.70
70.42
MSK
22
68.18
86.36
54.55
55
76.36
47.27
81.82
DFCI
5-year survival as the cutoff (high-risk: death within 5-y; low-risk: alive after 5-y)
125
72.80
72.80
44.80
104
66.35
69.23
93.27
UM & HLM
34
70.59
67.65
50.00
31
48.39
41.94
67.74
MSK
28
64.29
78.57
50.00
36
77.78
47.22
86.11
DFCI
2.5-year and 5-year survival as the high- and low-risk cutoffs (high-risk: death within 2.5-y; lowrisk: alive after 5-y)
84
75.00
77.38
48.81
104
66.35
69.23
93.27
UM & HLM
21
95.24
85.71
66.67
31
48.39
41.94
67.74
MSK
20
70.00
85.00
55.00
36
77.78
47.22
86.11
DFCI

According to the hazard ratio of the prognostic model for the three signatures in both test
cohorts, the 12-gene signature exhibited highest potential for lung cancer prognosis as it was the
only signature generated significant hazard ratio in stage I patients of both test cohorts. In
addition, the 12-gene signature accurately quantifies survival in patients in all stages, stage I
only, stage IB only, and patients in stage I or II who did not receive chemotherapy. The 12-gene
expression-defined risk score is a more accurate prognostic factor than commonly used clinical
parameters. Due to the high prognostication performance, chemoresponse prediction was further
studied using the 12-gene signature. Results show that the signature also predicts
chemoresistance and chemosensitivity to several major anti-lung cancer drugs in NCI-60 cancer
cell lines. Together, the results indicate that the 12-gene signature could be used to select early
stage lung adenocarcinoma patients at high risk for tumor recurrence for adjuvant chemotherapy.
Meanwhile, it may spare stage I and II low-risk patients from unnecessary chemotherapy.
Furthermore, the 12-gene signature has the potential to be used to inform physicians which
anticancer drugs should be used in treating a particular patient. The expression patterns of the 12gene signature were confirmed in RT-PCR. Curated interactions between the signature genes and
major cancer signaling hallmarks revealed in the functional pathway analysis provides further
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evidence that the 12-gene signature might be involved in lung cancer oncogenesis and tumor
progression.
Overall, the combinatorial gene selection scheme presented in this study identified 25
prognostic genes. This study demonstrates that combination of different stages of gene filtering
identified gene signatures with higher prognostic performance than traditional gene selection
approach. Feature selection algorithms included in the system is crucial not only to reduce the
size of the identified signatures but also to provide a set of genes with strong prognostic
classification. The choice to use a different feature selection technique depends on an evaluation
with an independent classifier. If the classification performance cannot be further improved with
the current algorithm, a different feature selection algorithm should be used. In conclusion,
hybrid models with combination of statistics and feature selection methods are efficient, robust,
and could identify prognostic gene signatures feasible for clinical utility.

Chapter 4
Network-based Models for Lung Cancer
Prognostic Signatures Identification
With the completion of the Human Genome Project, cataloging the “parts list” of disease genes
is no longer the focus of biomarker identification. Understanding the networks of interactions
that take place among the genes has become the new emphasis to identify marker genes because
the gene networks provide insights to unravel the molecular basis of disease [27]. Molecular
network analysis had been shown to be useful in disease classification [61] and identification of
novel therapeutic targets [115].

Nonetheless, the development of efficient methods for

constructing genome-wide coexpression networks and the identification of a particular set of
markers, from among the enormous number of potential markers, that has the highest predictive
ability for disease outcome remains the challenges for this research domain [7].
We had demonstrated that the combinatorial framework with multiple gene filtering
layers identify better prognostic genes signatures than traditional methods when being applied
alone. In this chapter, we will present another hybrid system that is built upon a computational
network model for the identification of lung cancer prognostic signatures. The network model
incorporated in the hybrid system is the implication networks induced from prediction logic [1].
With this network-based system, users could specify the signaling pathways and identify
signature genes that are tightly related to the set of signaling proteins in that particular pathway.
This presents an efficient framework for scientists to retrieve prognostic genes from the diseasemediated coexpression networks linked to signaling pathways. By combining additional layers
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of gene selection methods after retrieving prognostic genes from the modeled networks, sets of
gene signatures with strong prognostic classification performance were identified.
The remainder of the chapter is organized as follows.

Section 4.1 illustrates the

methodology of the proposed system and the identification of extensive prognostic gene
signatures for lung cancer. Section 4.2 presents the prognostic performance evaluation of the
identified signatures. Comparison of the identified signatures with all published lung cancer gene
signatures is discussed in Section 4.3. Section 4.4 describes the construction of molecular
prognostic classifiers and the performance using a particular signature identified, i.e. the 10-gene
signature. Functional pathway analysis was carried out to study the biological aspect of the
identified 10 genes to lung cancer oncogenesis and will be presented in Section 4.5. Section 4.6
presents the evaluation of the disease-mediated coexpression networks derived using the
implication network algorithm. The last section, Section 4.7 concludes the chapter.

4.1 Methodology
The methodology is based on the genome-wide coexpression networks modeled with the
implication networks. The implication induction algorithm (Fig. 2.7) was used to construct pairwise genome-scale coexpression networks for predicting risk from developing recurrence in lung
cancer.

The methodology was motivated by the hypothesis that the combined analysis of

disease-mediated genome-wide coexpression networks, signaling pathways, and clinical
approaches would lead to prognostic biomarker for more informed clinical use.
Patient samples from the largest public lung cancer microarray data published by
Shedden et al. [2] were used in this study. Training set was formed with patient samples from
UM and HLM (n = 256), whereas samples from MSK (n = 104) and DFCI (n = 82) constituted
two independent test sets. Data preprocessing were done before the analysis. First, whenever a
gene has missing measurements in at least half of the samples, the gene were removed from the
analysis.

Then, for genes measured using multiple probes, the average expression of the

duplicates was used to represent the expression profile of the unique gene. This gave a final set
of 12,566 unique genes for the implication network analysis.
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To construct implication networks, the mean expression of each gene in a patient cohort
was used as a cut-off to partition the expression profiles. If the expression of a gene in a patient
sample was greater than the mean in the cohort, this gene was denoted as up-regulated in this
tumor sample; otherwise, it was denoted as down-regulated in the tumor sample. In the training
set, patients who died within 5 years were labeled as poor-prognosis (n = 125), and those who
survived 5 years after surgery were labeled as good-prognosis (n = 104). Censored cases (those
with follow-up of less than 5 years) were removed from the analysis (n = 27). For each patient
group in the training set, a genome-wide coexpression network was constructed using the
implication induction algorithm. Between each pair of genes, possible significant (P < 0.05; onesided z-tests) coexpression relations were derived in each patient group, constituting diseasemediated gene coexpression networks. By comparing the implication rules connecting each pair
of nodes between the two networks, disease-specific differential network components were
identified. These differential components contain the coexpression relations that were either
present in the poor-prognosis group but missing in the good-prognosis group, or conversely,
those present in the good-prognosis group but missing in the poor-prognosis group (Fig. 4.1).
Next, candidate genes were obtained by retrieving genes displaying a direct significant (P
< 0.05, z-tests) co-regulation relation with major NSCLC signal proteins from the differential
components associated with each prognosis group. From the human NSCLC signaling pathways
delineated by the KEGG pathway database 8 , 11 signaling proteins (TP53, MET, RB1, EGF,
EGFR, KRAS, E2F1, E2F2, E2F3, E2F4, and E2F5) were included in this study. To analyze the
performance of methodology, candidate genes with significant coexpression relations with any
combination of 6 or 7 signaling proteins were included for further analysis (Fig. 4.1).
Three approaches were taken to identify gene signatures from the pool of candidate
genes.

In the first approach, probes with significant association with survival (P < 0.05,

univariate Cox model) were identified as signature genes. In the second approach, random
forests were used to obtain a refined set of signature genes from the significant probes (P < 0.05;
univariate Cox model). In the third approach, Relief algorithm was used to rank the significant
probes (P < 0.05; univariate Cox model), and a step-wise forward selection was used to
identified the final gene signatures. Specifically, starting from the top ranked gene, one gene
8

http://www.genome.jp/kegg/pathway/hsa/hsa05223.html
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was added at each step to the gene set, until the prognostic accuracy could not be improved by
adding more genes. The final gene set was identified as the gene signature. Fig. 4.1 gives an
overview of the methodology.

12,566 genes
Good-prognosis (n=104)

12,566 genes
Poor-prognosis (n=125)

Constructing coexpression networks
Implication network; prediction logic
Coexpression network
for good-prognosis

Coexpression network
for poor-prognosis

Comparing interaction patterns

Unique interactions for
good-prognosis

Unique interactions for
poor-prognosis

Identifying genes directly co-regulated with hallmarks
Pool of candidate genes
Univariate Cox Model (P < 0.05)
Genes associated with lung cancer survival

Random Forests
Prognostic gene
signatures (Approach 2)

Forward selection with Relief
Prognostic gene
Prognostic gene
signatures (Approach 1) signatures (Approach 3)

Figure 4.1. Overview of the study design for identifying prognostic gene signatures with implication
networks and feature selection methods.
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4.2 Evaluation of Identified Prognostic Gene Signatures
To evaluate if the identified signatures could provide accurate prognostic prediction for lung
adenocarcinoma, multivariate Cox proportional hazard model was used to construct prognostic
classifiers to stratify patients. On training samples, gene expressions of the identified prognostic
signature genes were fitted to the Cox proportional hazard models as covariates. Coefficients
obtained for each covariate in the constructed model were used to represent the training model.
Using the training model, a survival risk score was generated for each patient. From the training
risk scores, a cut-off value was identified to stratify patients into high- or low-risk groups. The
model and cutoff values defined using the training set were applied to the independent test sets
without re-estimating parameters. The prognostic performance of each identified gene signature
was evaluated according to the following criteria: log-rank tests in Kaplan-Meier analyses and
hazard ratio of death from lung cancer for all cancer stages, for stage I only and for stage I
without receiving chemotherapy in training and test cohorts. The prognostic performance of
patients from all tumor stages was evaluated on the two independent test sets individually. Due
to small sample size, the two independent test sets were combined while evaluating the
prognostic performance for stage I and stage I without receiving chemotherapy.
In the first approach, among the 462 sets of candidate genes that co-regulated with 6
signaling proteins, 9 gene signatures generated significant stratification (log-rank P <0.05) with
significant hazard ratios (P < 0.05) in all three patient cohorts (Table 4.1). Among these 9 gene
signatures, 5 of them also had significant hazard ratios (P <0.05) on stage I patients in all three
cohorts. Among the 5 gene signatures that could give accurate prognostic categorization in all
stages and stage I tumors, 4 gene signatures (referred to as S1-S4; Table B.1) generated
significant stratifications (log-rank P <0.05 in Kaplan-Meier analysis, with hazard ratio
significantly greater than 1) for stage I patients without receiving chemotherapy (Table 4.1).
Similarly, among the 330 sets of candidate genes co-regulated with 7 signaling proteins in the
first approach, 4 gene signatures generated accurate prognostic stratification (log-rank P <0.05 in
Kaplan-Meier analysis, with hazard ratio significantly greater than 1) in all three patient cohorts,
and one of them also generated accurate prognostic prediction in stage I patients in all three
datasets (Table 4.1). In the second approach, only 1 gene signature that co-regulated with 7
signaling proteins (referred to as S5; Table B.2) provided significant stratifications in patients
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with all tumor stages, stage I only, and stage I without receiving chemotherapy (Table 4.1). The
third approach identified 16 such gene signatures (referred to as S6 to S21; Table B.3) from the
candidate genes co-regulated with 6 signaling proteins.
In summary, a total of 21 gene signatures were identified using the three approaches in
this study, which, in turn, generated significant prognostic categorizations in lung
adenocarcinoma patients with all cancer stages, stage I only, and stage I without chemotherapy
(Table 4.1). These results demonstrate that the methodology provides a platform to efficiently
identify prognostic gene signatures which also co-regulate with major signaling proteins for lung
adenocarcinomas. Most importantly, the size of these gene signatures (4 ~ 33 genes) is feasible
to be further validated with biology experiments and used for clinical application.
Table 4.1. Summary of prognostic signature discovered using the methodology in the extensive
study.
No. of signatures giving significant stratifications (log-rank P< 0.05) in all dataset
Gene
Selection
Approach

Number of signaling
hallmarks

with significant hazard
ratio in all stages

&
with significant hazard
ratio in stage I *

&
with significant hazard
ratio in Stage I without
chemotherapy #

4
1
0
7
9
5
4
6
Average signature
21 genes
21 genes
24 genes
size
4
4
1
7
Network +
3
2
0
6
Random
Forests
Average signature
12 genes
10 genes
5 genes
(Approach 2)
size
7
4
0
7
Network +
47
26
16
6
Relief
(Approach 3) Average signature
14 genes
12 genes
14 genes
size
Total number of
Summary
74
42
21
signatures
* Gene signatures in this column also had significant hazard ratio in all cancer stages in all three patient cohorts.
# Gene signatures in this column also have significant hazard ratio in all cancer stages in all three patient cohorts
and stage I in training and combined test cohorts.
Networkbased
(Approach 1)
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4.3 Comparison with other Lung Cancer Gene Signatures
To further investigated the prognostic performance of the 21 prognostic signatures identified
from the proposed methodology, we compared the signatures with gene expression-based lung
cancer signatures reported to date. Eleven lung cancer gene signatures were evaluated in the
Director’s Challenge Study [2], among which five of them were identified from previous studies
on lung cancer molecular prognosis [15, 16]. Among the 11 gene signatures evaluated, the best
signature reported was “method A” (referred to as “A” in Fig. 4), which contains about 9,591
genes/probes. The prognostic performance of our gene signatures was compared with the best
lung cancer gene signatures reported to date in terms of the estimated hazard ratio and the
concordance probability estimate (CPE) in two test sets (Fig. 4.2A and 4.2B).
Results from the comparison show that the 21 gene signatures (S1-S21) identified in this
study perform better than all other previously identified lung cancer gene signatures (Fig. 4.2).
Among the 11 previously identified gene signatures, “method A” is the only model with hazard
ratio significantly (P < 0.05) greater than 1 in all three patient cohorts (Fig. 4.2A). On the other
hand, all 21 gene signatures identified from the proposed system generated hazard ratio
significantly (P < 0.05) greater than 1 in all three patient cohorts (Fig. 4.2A). Moreover, all 21
gene signatures had a significant hazard ratio and a CPE significantly greater than 0.5 (P<0.05)
in stage I patients (Fig. 4.2C-4.2D). Most significantly, the 21 identified signatures also had
significant hazard ratio and CPE in stage I patients without receiving chemotherapy (Fig. 4.2E4.2F), which is a prognostic capacity which has not been reported in the previous studies [2, 15,
16].
These results demonstrate that the gene signatures discovered with the network-based
methodology are clinically important in identifying specific high-risk patients diagnosed with
early stage lung adenocarcinoma for adjuvant chemotherapy.
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Figure 4.2. Comparison of 21 identified gene signatures with other lung cancer gene signatures.
The 21 prognostic gene signatures were compared with 11 gene signatures evaluated in the Director’s
Challenge Study [2] in two test sets in terms of hazard ratio (A) and concordance probability estimate
[CPE] (B). The prognostic performance of the 21 gene signatures was evaluated for stage I patients by
hazard ratio (C) and CPE (D), as well as for stage I patients without receiving chemotherapy in the
combined test cohorts (E, F). The error bar in the charts represents 95% confidence interval of the
measurement.
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4.4 Survival Prediction Using the Identified 10-gene
Prognostic Signature
To confirm the prognostic performance of the identified signatures, we further evaluated one of
the 21 identified signatures. A 10-gene signature identified using the third approach (S13; was
Table B.3) was selected for further evaluation. From the disease-mediated prognosis groups, 154
candidate prognostic genes showed direct coexpression with signaling proteins EGF, KRAS,
TP53, RB1, E2F1, and E2F2; in which 57 were identified from the good-prognosis group and
106 were identified from the poor-prognosis group (with 9 genes common in both groups). From
the training set of the original continuous microarray data, 26 probes out of these 154 genes were
significantly associated with overall survival (P < 0.05, univariate Cox mode). Based on the
forward selection and ranking with Relief [116], the top 10 genes were identified as the final
signature (S13; Table B.3).
Multivariate Cox proportional hazard model was fitted with the 10 genes as covariates on
bootstrapped training samples for 1,000 times. The average of the 1,000 coefficients obtained
for each covariate was used to represent the final coefficients in the training model. Using the
training model, a survival risk score was generated for each patient. A risk score of -12.04 was
identified as a cut-off value for patient stratification in the training set (Fig. 4.3A). This training
model and cut-off value was then applied to the two validation sets to generate prognostic
categorization without re-estimating parameters (Fig. 4.3B and 4.3C). In all three patient cohorts,
this scheme stratified patients into two prognostic groups with significantly distinct survival
outcome (log-rank P < 0.03, Kaplan-Meier analyses). When the high-risk group is defined as a
group of patients who survived 5 years or less, and the low-risk group with patients who
survived 5 years or longer, this model accurately classify 64% of the patients on training, 57% on
MSK and 66% on DFCI. The model also achieved sensitivity (correctly predicted high-risk
patients) of 55.20% on the training set, 52.94% on MSK, and 75% on DFCI. The specificity
(correctly predicted low-risk patients) was 75% on the training set, 61.29 % on MSK, and
58.33% on DFCI (Fig. 4.3D).
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Figure 4.3. Prognostication of disease-specific survival using the 10-gene signature in lung
adenocarcinoma patients. The model stratified patients into two prognostic groups with significantly
different (P < 0.03) survival outcome in the training set UM&HLM (A) and both test sets MSK (B) and
DFCI (C) in Kaplan-Meier analyses. Log-rank tests were used to assess the difference in survival
probability between the two prognostic groups. Performance of 5-year survival prediction on training and
two test sets (D).

Furthermore, the 10-gene prognostic signature could identify high-risk patients with stage
I cancers on both the training set and combined test sets (log-rank P ≤ 0.007; Fig. 4.4A-4.4B).
The prognostic model also successfully separated high- and low-risk groups within stage IB
patients in the training and combined test sets (log-rank P ≤ 0.04; Fig. 4.4C-4.4D). In stage I
patients who did not receive chemotherapy, the prognostic model stratified high- and low-risk
groups with distinct survival outcome in both training and test sets (log-rank P ≤ 0.04; Fig. 4.4E4.4F). These results demonstrate that the 10-gene signature provides a more refined prognosis
than the current AJCC staging system. Using this model, patients with stage I NSCLC could be
advised to either receive or be spared from chemotherapy according to the expression profiles of
the 10 prognostic genes.
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Figure 4.4. Prognostic performance of the 10-gene signature in stage I lung adenocarcinoma. The
model generated significant prognostic categorization for stage I patients in both training set UM&HLM
(A) and combined test sets MSK&DFCI (B), for stage IB patients in training (C) and combined test sets
(D), as well as for stage I patients without receiving chemotherapy in both training (E) and combined test
sets (F). Statistical significance of the difference in survival probability between the two prognostic
groups was assessed with log-rank tests in Kaplan-Meier analyses.

4.5 Prognostic Evaluation with Clinical Covariates
To further validate the prognostic power of the model, the constructed 10-gene prognostic model
was evaluated with common lung cancer prognostic factors using multivariate Cox analysis on
the combined testing cohorts (MSK and DFCI). The constructed 10-gene risk score algorithm
was evaluated using clinical factors, including gender, age, cancer stage, smoking history, race,
and tumor differentiation. In the analysis without the 10-gene risk score, among major clinical
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cal covariates age, gender and cancer stage, cancer stage was the only significant predictor of
death from lung cancer (Table 4.2). After the 10-gene risk score was included, the gene risk
score became a highly significant prognostic factor with a hazard ratio of 3.63 (95% CI: [1.70,
7.77]). The hazard ratio of the gene risk score was higher than other clinical covariates, except
cancer stage (III vs. I; with no significant difference). Similar results were obtained in the more
comprehensive analysis with all the clinical covariates (Table 4.3). These results demonstrate
that the 10-gene signature is a more accurate prognostic factor than most commonly used clinical
factors.
Table 4.2. Multivariate Cox proportional hazard analysis of the 10-gene risk score and major
clinical covariates including gender, age, and tumor stage on the combined testing cohorts (MSK
and DFCI).

Variable*
P-value
Analysis without 10-gene risk score
Gender (Male)
0.22
Age at diagnosis (>60) 0.08
Cancer Stage
Stage II
6.25E-05
Stage III
1.09E-05
Analysis with 10-gene risk score
Gender (Male)
0.28
Age at diagnosis (> 60) 0.09
Cancer Stage
Stage II
1.62E-04
Stage III
4.58E-06
10-gene risk score
8.61E-04

Hazard Ratio (95% CI) ψ

1.34
1.61

(0.84,2.16)
(0.95,2.74)

2.91
4.16

(1.72,4.91)
(2.20,7.85)

1.30
1.59

(0.81, 2.09)
(0.93, 2.70)

2.74
4.45
3.63

(1.62, 4.63)
(2.35, 8.43)
(1.70, 7.77)

* Gender was a binary variable (0 for female and 1 for male); age at diagnosis was a binary variable (0 for < 60
years old and 1 otherwise); cancer stage was a categorical variable with 3 categories (Stage I [as the reference
group], Stage II, and Stage III).
ψ
denotes confidence interval.
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Table 4.3. Multivariate Cox proportional analysis of all available clinical covariates and 10-gene
risk score in the combined test cohorts (MSK and DFCI).

Variable*
P-value
Analysis without 10-gene risk score
Gender (Male)
0.43
Age at diagnosis (>60)
0.05
Race
Others/Unknown
0.28
White
0.10
Smoking history
Smokers
0.62
Unknown
0.91
Tumor differentiation

Moderately differentiated
0.14
Poorly differentiated
0.70
Cancer Stage
Stage II
3.31E-04
Stage III
2.38E-05
Analysis with 10-gene risk score
Gender (Male)
0.37
Age at diagnosis (>60)
0.05
Race
Others/ Unknown
0.20
White
0.10
Smoking history
Smokers
0.81
Unknown
0.87
Tumor differentiation
Moderately differentiated
Poorly differentiated
Cancer Stage
Stage II
Stage III
10-gene risk score

Hazard Ratio (95% CI)ψ

1.22 (0.74,1.99)
1.70 (0.99,2.92)
0.43 (0.09,1.97)
0.28 (0.06,1.28)
(0.00,0.00)
0.84 (0.43,1.66)
0.89 (0.11,7.10)
0.53 (0.23,1.24)
1.17 (0.53,2.61)
2.72 (1.57,4.69)
4.93 (2.35,10.33)
1.25 (0.76, 2.04)
1.69 (0.99, 2.89)
0.37 (0.08, 1.67)
0.28 (0.06, 1.25)
0.92 (0.47, 1.80)
1.18 (0.15, 9.64)

0.13
0.81

0.52 (0.23, 1.21)
1.10 (0.50, 2.41)

4.19E-04
3.47E-05
3.31E-03

2.66 (1.54, 4.58)
4.79 (2.28, 10.05)
3.23 (1.48, 7.06)

* Gender was a binary variable (0 for female and 1 for male); age at diagnosis was a binary variable (0 for < 60
years old and 1 otherwise); race was a categorical variable of 3 categories (African American [as the reference
group], White, and Others [composed of Asian (5) , Hawaiian or Pacific Islander (1), and unknown]); tumor grade
was categorical variable of 3 categories (Well [as the reference group], Moderately, and Poorly differentiated);
Smoking history was a categorical variable of 3 categories (Non-smokers, Smokers, and Unknown); cancer stage
was a categorical variable with 3 categories (Stage I [as the reference group], Stage II, and Stage III).
ψ
denotes confidence interval.
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4.6 Functional Pathway Analysis
Having established the prognostic performance of the 10 prognostic genes identified, we sought
to explore the functional involvement of this gene set in lung tumorigenesis and tumor
progression. Curated molecular interactions between the major NSCLC signaling pathways and
the identified 10-gene signature were retrieved using functional pathway analysis tools,
Ingenuity Pathway Analysis (IPA, Ingenuity® Systems). The IPA functional pathway analysis
demonstrated that nine canonical pathways were significantly (P<0.05; adjusted with BH tests)
associated with the 10 prognostic genes. These pathways include methane metabolism and
phenylalanine metabolism related to cell cycle, eicosanoid signaling that mediates inflammation
and immunity, and MAPK signaling related to cell death, tissue morphology and inflammatory
response (Fig. 4.5A). The pathway analysis also showed that cancer is among the top 5 most
significant disease and disorders (P<0.05; adjusted with BH tests) in the network related to the
10 prognostic genes (Fig. 4.5B). Furthermore, 4 of the 10 prognostic genes were involved in
interactions with major lung cancer signaling proteins, including TP53, KRAS, EGF, E2F1, and
RB1 as reported in the literature (Fig. 4.5C). These results suggest that the identified 10 genes are
involved in lung cancer oncogenesis and tumor progression.
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Figure 4.5. Functional pathway analysis of the 10 prognostic genes. Core analysis was performed
with Ingenuity Pathway Analysis (IPA). Significant canonical pathways retrieved from IPA (A).
Cancer was a significant biological function in the disease and disorders category (B). Curated
interactions related to the 10 signature genes were also revealed from the literature (C).

4.7 Evaluation of Disease-mediated Gene Coexpression
Networks
We further examined the disease-mediated coexpression networks derived from the system. The
coexpression relations among the 10 signature genes and the 6 signaling proteins specific to each
prognostic group were retrieved. Those commonly present in both training and test sets were
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considered robust for further study and biological evaluation. There were 4 common
coexpression relations specific to good-prognosis group (Fig 4.6A) and 2 specific to poorprognosis group (Fig 4.6B) in both training and test sets.

These 6 coexpression relations

represent the gene coexpression patterns specifically associated with metastasis in lung cancer
patients. Among these 6 coexpression relations, the interaction between CPEB1 and TP53 was
confirmed in a reported study [117] (Fig. 4.6A). Based on the five gene collections from
MSigDB 9 , the disease-mediated coexpression networks were also assessed in term of precision
and false discovery rate (FDR).

In 1,000 permutations, the precision of disease-mediated

coexpression networks is 1 (P <0.001) and the FDR is 0. These results indicate that implication
networks can reveal biologically relevant gene associations. Moreover, results from the stability
test showed that more than 60% of the coexpression relations confirmed in the test set could be
derived by using as few as 70% of the training samples, indicating the implication network
algorithm is stable (Fig. 4.6D).
In addition to the 10-gene signatures, biological robustness of the other 20 identified
signatures was also evaluated with the known molecular relations found in MSigDB. For each
gene signature, the coexpression relations among the signature genes and their co-regulated
signaling proteins were generated for each prognosis groups and those commonly found in
training and two independent test cohorts were retrieved for the assessment (Fig. C.1 – C.22).
Results show that two signatures (S2, S7) generated coexpression networks with the most
coexpression relations derived incorrectly with FDR of 0.1 (-log(FDR) = 1, Fig. 4.7)). One the
other hand, the disease-mediated coexpression networks for seven of the 21 signatures (including
the 10-gene signature) has FDR < 0.001 (-log(FDR) ~ 3; Fig. 4.7). These results demonstrate
that the coexpression relations derived from the implication relation induction algorithm are
successfully validated with molecular interactions reported in the literature.

9

http://www.broadinstitute.org/gsea/msigdb/collections.jsp
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Figure 4.6. Disease-specific coexpression relations among the 10 prognostic signature genes and the 6
lung cancer signaling proteins. The disease-specific expression patterns for the good-prognosis group (A)
and the poor-prognosis group (B) that were commonly present in both training and test cohorts were illustrated.
The interpretation of the coexpression patterns is provided in (C). The stability of the networks in (A) and (B)
was evaluated by using random subsets of the training samples in 100 iterations (D).

Figure 4.7. False discovery rate of the disease-mediated coexpression networks for the identified 21
prognostic signatures. The false discovery rate of the disease-specific coexpression relations among the
signature genes and co-regulated hallmarks found in all three studied cohorts validated with MSigDB in
1,000 permutations.
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4.8 Conclusions
This study presents a novel network-based methodology for modeling gene coexpression
networks with major NSCLC signaling hallmarks for biomarker identification. The network
model is flexible; it could be used alone, or in conjunction with other gene selection algorithms,
such as random forests or Relief, in signature identification. This study demonstrates that the
implication network methodology based on prediction logic is suitable for constructing genomewide coexpression networks for analyzing perturbed gene/protein expression patterns in different
disease states. The disease-mediated differential network components may contain important
information for the discovery of biomarkers and pathways with implications for prognostic
prediction. The implication network methodology provides a convenient and more predictive
structure of gene regulation than the networks constructed based on correlation coefficients.
Our previous study identified a 12-gene signature using hybrid models combining t-test,
significant analysis of microarray (SAM), and Relief algorithm [118]. The hazard ratio of the 12gene signature was significant for all cancer stages in three patient cohorts, but not significant in
any test sets for stage I only in the Director’s Challenge Study. The network-based methodology
presented in this chapter demonstrates the extensive identification of lung cancer prognostic gene
signatures with strong prognostication performance in all tumor stages, stage I only, and stage I
patients without receiving chemotherapy. All 21 gene signatures identified in this study
outperformed other lung cancer signatures reported in the literature on the same patient cohorts.
Most importantly, the identified signatures were all in feasible size to be further validated with
biology experiments. These results indicate that modeling disease-mediated coexpression
networks and crosstalk with NSCLC signaling hallmarks is crucial to identifying clinically
important biomarkers for lung cancer. The identified gene signatures could potentially be used to
advise patient selection for adjuvant chemotherapy in personalized lung cancer treatment.
The discovered gene signatures may also reveal essential molecular mechanisms of the
disease and enhance our understanding of why patients with certain molecular tumor
characteristics have a poor clinical outcome and how their outcome could be improved.
Functional pathway studies with IPA confirmed the interactions between the major NSCLC
signaling pathways and the identified gene signatures.
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In addition to the 10-gene signature discussed in the chapter, a 14-gene and 13-gene
prognostic signature was identified using the third approach of the implication network-based
methodology [119, 120]. The 14-gene prognostic signature was identified from genes having
direct coexpression relation with TP53, KRAS, EGF, EGFR, E2F3, and E2F4 [120]; where the
13-gene prognostic signatures were directly co-regulated with MET, EGF, KRAS, TP53, E2F2,
and E2F4 in the disease-mediated differential network components [119]. Both these signatures
generated significant patient stratification on the training set and two validation sets, with all
tumor stage, and stage IB. However, they could not generate significant stratifications on both
test cohorts of stage I patients and stage I patients without receiving chemotherapy. In patients
with all tumor stages, the prognostic performance of the 14- and 13-gene signatures is
comparable to the 10-gene signature presented in this chapter. (Table 4.4).
Table 4.2. Sensitivity and specificity of the 13- and 14-, and 10-gene gene prognostic models.
Sensitivity (% of correctly predicted
high-risk patients)

Specificity (% of correctly
predicted low-risk patients)

n
13-gene
14-gene
10-gene
n
13-gene
14-gene 10-gene
3-year survival as the cutoff (high-risk: death within 3-y; low-risk: alive after 3-y)
95 56.84
52.63
58.95
152 75.66
67.76
73.03
UM & HLM
23 73.91
78.26
65.22
71
54.93
45.07
63.68
MSK
22 68.18
90.91
77.27
55
56.36
34.55
58.18
DFCI
5-year survival as the cutoff (high-risk: death within 5-y; low-risk: alive after 5-y)
125 52.00
53.60
55.20
104 77.88
73.08
75.00
UM & HLM
34 67.65
79.41
52.94
31
51.61
51.61
61.29
MSK
28 67.86
89.29
75.00
36
61.11
30.56
58.33
DFCI
2.5-year and 5-year survival as the high- and low-risk cutoffs (high-risk: death within 2.5-y; low-risk:
alive after 5-y)
84 59.52
51.19
59.52
104 77.88
73.08
75.00
UM & HLM
21 76.19
76.19
61.90
31
51.61
51.61
61.29
MSK
20 70.00
90.00
75.00
36
61.11
30.56
58.33
DFCI

These results conclude that the presented implication network-based methodology
accurately model the disease relevant gene coexpression patterns for the discovery of clinically
important prognostic gene signatures. Most importantly, gene signatures identified with this
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novel network-based methodology provide strong prognostic performance and in viable size for
biology validation and clinical application.

Chapter 5
Network-based Identification of Smokingassociated Gene Signature for Lung
Cancer
Studies have demonstrated that smoking contributes to about 90% of all lung cancer cases and it
appears to be a strong risk factor in the development of lung cancer [108, 121, 122]. However,
smoking is not an established determinant in lung cancer prognosis as its effect in lung cancer
progression remains unclear. In this study, we sought to identify a smoking-associated gene
signature with implications in lung cancer diagnosis and prognosis using genome-wide
transcriptional profiles from lung cancer patients.
In the previous chapter, implication networks were employed to model disease-mediated
genome-wide coexpression networks for the identification of prognostic gene signatures. In this
study, implication networks were used to infer the relevance to signaling pathways in a set of
selected genes associated with smoking and lung cancer survival.
This chapter is organized into ten sections. The first section presents the methodology.
Section 5.2 describes the identification of the smoking-associated signature using the proposed
methodology. Prognostic evaluation of the identified signature will be presented in Section 5.3.
Section 5.4 provides the results on association study between the signature and smoking. The
prognostic evaluation of the signature with clinical covariates is presented in Section 5.5.
Section 5.6 validates the prognostic performance of the signature on different subtypes of
NSCLC. Results on potential usage of the signature for early detection of lung cancer will be
95
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presented in Section 5.7. The assessment of interactions retrieved using implication networks
will be discussed in Section 5.8. Biology eexperiment validation result is presented in Section
5.9. The conclusions of the study will be discussed in Section 5.10.

5.1 Methodology
The methodology studied in this chapter is similar to the implication network-based system
illustrated in Chapter 4. Major difference between the two methodologies is that the gene
coexpression networks were not modeled for the whole genome in this study. Instead of the
whole genome, the implication networks were used to model coexpression patterns of a smaller
pool of genes: genes associated with smoking and also prognostic for lung cancer.

This

application also demonstrates the use of implication networks in modeling gene coexpression
patterns mediated with the smoking practice, instead of disease outcome as studied in Chapter 4.
Specifically, the methodology contains the following steps: 1) identifying genes
significantly associated with lung cancer survival, 2) from the survival genes, selecting genes
which are differentially expressed in smoker versus non-smoker groups, 3) from these candidate
genes, constructing gene co-expression networks based on prediction logic for smokers and nonsmokers, 4) identifying smoking-mediated differential components, i.e., the unique gene coexpression patterns specific to smoker group or non-smoker group, and 5) from the differential
components, identifying genes directly co-expressed with major lung cancer hallmarks as the
smoking-associated gene signature for lung cancer (Fig. 5.1).
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Genome-wide expression profiles
(Training set)
Univariate Cox (P < 0.05)

Genes associated with NSCLC survival
t-tests (smokers vs Non-smokers, P < 0.05)

Genes differentially expressed in
smokers vs non-smokers and
significantly associated with survival

NSCLC hallmarks

Implication networks

Coexpression networks for smoker NSCLC

Coexpression network for non-smoker NSCLC

Comparing coexpression types

Unique interactions for smoker NSCLC

Unique interaction for non-smoker NSCLC

Identifying genes directly interact with 6 hallmarks

Smoking-associated gene signature

Figure 5.1. Methodology for network-based identification of smoking-associated signatures.

5.2 Identification of a Smoking-associated 7-gene Signature
In this study, 442 lung adenocarcinoma patient samples obtained from the Director’s Challenge
Study [2] were used. In this study, the UM and HLM cohorts from the Director’s Challenge
Study [2] formed the training set (n=256), whereas MSK and DFCI cohorts formed the test set
(n=186). Before the analysis, genes with missing values in at least half of the samples were
removed, which left 19,866 genes for the analysis.
Survival genes were first selected from the whole genome. A total of 2,310 genes were
significantly associated with overall survival (P < 0.05, univariate Cox modeling) in the training
data. Next, from the set of 2,310 survival genes, 217 genes showed significant differential
expression (P < 0.05, t-tests) in smokers versus non-smokers in the training data were further
extracted. These 217 survival and smoking-associated genes as well as six major signaling
proteins, including EGF, EGFR, MET, KRAS, E2F3, and E2F5, were included in the network
analysis. Although these six hallmarks were not significantly associated with survival nor
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differentially expressed in smokers, they were major signaling proteins included in human nonsmall cell lung cancer disease mechanisms delineated by the KEGG Pathway Database 10 .
To construct implication networks, expression profiles in each patient were partitioned
into binary values using the mean expression profile of each gene as the cutoff. If the expression
of a gene in a patient sample was greater than the mean in the cohort, this gene was denoted as
up-regulated in this tumor sample; otherwise, it was denoted as down-regulated in the tumor
sample. Patient samples in the training set were separated into two groups: smokers (patients
who smoked in the past or who are currently smoking) and non-smokers (patients who never
smoked). For each patient group, coexpression network among the 217 genes and six signally
hallmarks was constructed using the implication induction algorithm. Between each pair of the
223 genes, possible significant (P < 0.05; z-tests) coexpression relations (interactions) were
derived in the smoker group and the non-smoker group separately, constituting smokingmediated gene co-expression networks for lung cancer. By comparing the implication rules
between each pair of nodes in the two smoking-mediated networks, differential network
components were identified. These differential components are interactions that were present in
the smoker group but missing in the non-smoker group, or conversely, those present in the nonsmoker group but absent in the smoker group.
From the differential components associated with smoker group and non-smoker group,
genes having direct interactions with the six lung cancer hallmarks were identified. As a result,
six genes were identified from the smoker group and one gene was identified from the nonsmoker group.

This constituted the smoking-associated 7-gene signature for lung cancer

prognosis (Table 5.1). Fig. 5.2 gives an overview of the whole methodology.
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19,866 genes
Director Challenge’s Study (Training set, n=256)
Univariate Cox (P < 0.05)

2,310 genes
Associated with NSCLC survival
t-tests (smokers vs Non-smokers, P < 0.05)

217 genes
Differentially expressed in smokers vs nonsmokers and significantly associated with survival

6 NSCLC hallmarks
EGF, EGFR, MET, KRAS, E2F3, E2F5

Implication networks

Coexpression networks for smoker NSCLC

Coexpression network for non-smoker NSCLC

Comparing coexpression types

Unique interactions for smoker NSCLC

Unique interaction for non-smoker NSCLC

Identifying genes directly interact with 6 hallmarks

Smoking-associated 7-gene signature

Prognostic Validation
Multiple microarray data; Cox
model, Chi-square analysis, k-NN

Biological Network Validation
Pathway Studio, KEGG, NCIPathway, STRING 8, PubMed

Experimental Validation
NNK-treatment in cell lines
H23 and BEAS-2B

Figure 5.2. Identification of 7-gene smoking-associated signature.

Table 5.1. The identified 7-gene smoking associated signature.
Gene
Symbol
ABCA3
CRTAC1
CYP3A4
GPRC5C
LTF
PIGN
SEMA3C

Gene Title

Molecular Function (Gene Ontology)

ATP-binding cassette, sub-family A (ABC1),
member 3
Cartilage acidic protein 1

ATP, nucleotide binding; ATPase, transporter
activity
Calcium ion binding

Cytochrome P450, family 3, subfamily A,
polypeptide 4
G protein-coupled receptor, family C, group 5,
member C
Lactotransferrin

Monooxygenase, electron carrier, oxidoreductase
activity; heme, metal ion, and steroid binding
Receptor activity; protein binding

Phosphatidylinositol glycan anchor
biosynthesis, class N
Sema domain, immunoglobulin domain (Ig),
short basic domain, secreted, (semaphorin) 3C

Ferric iron, heparin, metal ion, protein binding;
peptidase, serine-type endopeptidase activity
Phosphotransferase, transferase activity
Receptor activity; semaphorin receptor binding
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5.3 Prognostic Evaluation of the Signature
We sought to study if the gene signature identified could provide accurate prognostic prediction
of survival for lung cancer patients. The six hallmarks were not fitted in the model as they were
not significantly associated with survival.

On the training cohort, the original continuous

expression profiles of the seven probes were fitted into a Cox proportional hazard model as
covariates. A survival risk score was generated for each patient in the training set. To identify
the best patient stratification scheme, various cutoff values of the risk scores from the training set
were evaluated.

The cutoff value that gave the shortest distance to the point of perfect

prediction, i.e. point [0,1] of the 3-year ROC curve (Fig. 5.3A), produced the best patient
stratification in the training set (Fig. 5.3B). Therefore, the training model and cutoff value were
applied to the test set (Fig. 5.3C). In both training and test set, this classification scheme
generated significant patient stratifications (log-rank P < 0.007, Kaplan-Meier analysis).
To evaluate the statistical significance of the signature identified from the proposed
network analysis, a set of seven genes from the 217 survival and smoking-associated genes were
randomly selected and constructed as a classifier using the same approach with the Cox
proportional hazard model. Results showed that the signature identified gave significantly (P <
0.04) better lung cancer prognosis compared with 1000 random signatures.

Figure 5.3. Prognostic prediction of patients survival by smoking-associated gene signature. On the
cohorts from Shedden et al. [2], the risk score giving the best prediction on the 3-year ROC curve was
identified as the cutoff for patient stratification (A). This cutoff value generated significant patient
stratification on the training set (B), test set (C), and smokers of test set (D) in Kaplan-Meier analyses.
Log-rank tests were used to assess the statistical significance in survival probability between the two
prognostic groups.
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5.4 Smoking Association and Smoking Cessation
To evaluate the smoking association of the identified gene signature, we evaluated the
performance of the prognostic signature on smokers in the studied cohorts. Results showed that
the signature gave accurate prognostic prediction in smokers in the test cohort (log-rank P <
0.01, Kaplan-Meier analysis) (Fig. 5.3D) but not in non-smokers (log-rank P < 0.12, KaplanMeier analysis, results not shown). In addition, gene expression-defined high and low-risk
groups showed significant association with smoking (P < 0.02, Chi-square tests) and smoking
cessation (P < 0.00001, Chi-square tests) (Table 5.2). Specifically, smokers were significantly
associated with high-risk group compared with non-smokers, and current smokers showed a
stronger association with the high-risk group compared with former smokers.
Table 5.2. Associations between smoking status and the classifier's prediction.

Smoker
Non-smoker
Current Smoker
Former Smoker

Low-risk

High-risk

143
33
3
140

157
16
29
128

Chi-square Test
Smoking association
χ2 = 5.76 (P = 0.02)
Smoking cessation
χ2 = 19.37 (P = 1.08e-5)

5.5 Prognostic Evaluation with Clinical Covariates
To validate the prognostic power of the identified 7-gene signature, the constructed expressiondefined prognostic model was evaluated with common lung cancer prognostic factors, including
gender, age, tumor stage, and tumor differentiation on smokers in the test cohort. The predicted
7-gene risk score was used as the covariate in the multivariate Cox analysis.
Results from the multivariate Cox proportional analysis showed that tumor stage was the
only factor significantly (P < 0.002) associated with elevated risk of lung cancer death when the
model was fitted without the 6-gene prognostic prediction (Table 3). When the 7-gene risk score
was added to the multivariate Cox model, the 7-gene risk score demonstrated a significantly
strong association with the risk of lung cancer death (hazard ratio = 1.89, 95% CI: [1.06, 3.38]),
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and tumor stage remained significant (Table 3). The hazard ratio of the 7-gene risk score was
higher than other cancer prognostic factors except tumor stage, while there is no significant
difference between the hazard ratio of the 7-gene risk score and tumor stage (II vs. I). The
results demonstrate that the 7-gene risk score could provide more accurate prognosis than some
commonly used clinical parameters.
Table 3. Multivariate Cox proportional analysis of the 7-gene risk score and major clinical
covariates in smoking lung cancer patients of the test cohort.

Variable*
P-value
Analysis without 7-gene risk score
Gender (Male)
0.55
Age at diagnosis (>60)
0.35
Tumor differentiation
Moderately differentiated
0.30
Poorly differentiated
0.89
Cancer Stage
Stage II
1.54E-03
Stage III
5.53E-05
Analysis with7-gene risk score
Gender (Male)
0.51
Age at diagnosis (>60)
0.49
Tumor differentiation
Moderately differentiated
0.33
Poorly differentiated
0.93
Cancer Stage
Stage II
1.64E-03
Stage III
3.29E-05
7-gene risk score
0.03

Hazard Ratio (95% CI)ψ

1.17 (0.70, 1.95)
1.31 (0.74, 2.29)
0.63 (0.26, 1.51)
1.06 (0.47, 2.38)
2.60 (1.44, 4.71)
4.48 (2.16, 9.29)
1.19 (0.71, 1.99)
1.22 (0.69, 2.16)
0.65 (0.27, 1.55)
0.96 (0.43, 2.16)
2.61 (1.44, 4.74)
4.79 (2.29, 10.04)
1.89 (1.06, 3.38)

* Gender was a binary variable (0 for female and 1 for male); age at diagnosis was a binary variable (0 for < 60
years old and 1 otherwise); tumor grade was categorical variable of 3 categories (Well [as the reference group],
Moderately, and Poorly differentiated); tumor stage was categorical variable of 3 categories (Stage I [as the
reference group], Stage II, and Stage III).
ψ
denotes confidence interval.
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5.6 Prognostic Validation on other Histology Subtypes of
NSCLC
The prognostic performance of the 7-gene signature was further evaluated on Raponi [17] and
Bild [13] cohorts including squamous cell carcinoma. Due to small sample size, patient samples
in the studied cohort were randomly partitioned into separate training and test sets. Then, a
prognostic classifier was constructed on training set using the Cox proportional hazard model
and validated on the test set without re-estimation of parameters. On Raponi’s cohort with
squamous cell carcinoma patients, the 7-gene signature stratified patients into two distinct
survival groups (log-rank P < 0.005, Kaplan-Meier analysis) in the training set but border line in
the test set (Fig. 5.4A, 5.4B). The border line performance in the test cohort could be due to the
reason that 8 percent of the patients in the cohort were non-smokers and the 7-gene prognostic
signature is specific to smokers. On the Bild’s cohort with lung adenocarcinoma or squamous
cell carcinoma patients, the 7-gene signature stratified patients into two distinct survival groups
in both training and test set (log-rank P < 0.04, Kaplan-Meier analysis) (Fig. 5.4C, 5.4D).

Figure 5.4. Prognostic prediction of patient survival by the smoking-associated gene signature on
two cohorts with different histology. In Kaplan-Meier analyses, significant patient stratifications were
also obtained in the training and test sets on cohorts from Raponi et al. [17] (A, B) and Bild et al. [13] (C,
D). Log-rank tests were used to assess the statistical significance in survival probability between the two
prognostic groups.
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5.7 Early Detection of Lung Cancer
We further evaluated whether the 7-gene signature could be used for the diagnosis of lung cancer
in smokers. The smoking cohort from Spira et al. [108] was separated into a training set (n=77)
and two independent test sets (n=52 and n=35). With the nearest neighbor algorithm
implemented in WEKA [116], the classifier could accurately identify lung cancer patients from
normal patients with overall accuracy of 65% in training and 73% or higher in test sets (Table
5.3). The sensitivity in identifying lung cancer patients is at least 72% (Table 5.3). The odds
ratio of predicted lung cancer risk was highly significant in all three sets (OR = 3.85, 95% CI:
[1.45, 10.20], P < 0.007 in training; OR = 7.35, 95% CI: [2.16, 25.04], P < 0.001 in Test set 1;
OR = 8.45, 95% CI: [1.84, 38.75], P < 0.006 in Test set 2; Table 5.3). Furthermore, the
classifier’s performance was significantly (P < 0.002) better than that of random signatures with
the same size using the same classifier in 1000 tests, on the same training and test sets.
Table 5.3. Prediction of lung cancer risk in smokers.

Sensitivity
(lung cancer)
Training (10-fold CV) 74% (26/35)
72% (18/25)
Test 1
72% (13/18)
Test 2

Specificity
Overall
(normal)
Accuracy
57% (24/42) 65% (50/77)
74% (20/27) 73% (38/52)
76% (13/17) 74% (26/35)

Odds Ratio
P-value
[95% CI]
3.85 [1.45, 10.20] 0.007
7.35 [2.16, 25.04] 0.001
8.45 [1.84, 38.75] 0.006

5.8 Assessment of Smoking-mediated Gene Coexpression
Networks
To assess the smoking-mediated coexpression relations derived by the implication network,
differential network components among the signature genes and the six signaling hallmarks
present in both training and test sets were retrieved as they were consider robust for further
evaluation. There were 17 common interactions specifically associated with smokers (Fig. 5.5A)
and one interaction specifically associated with non-smokers (Fig. 5.5B).
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The biological relevance of the derived coexpression relations was validated by retrieving
curated interactions related to these genes using bioinformatics tools including Pathway Studio
(Fig. 5.5D) and other curated signal pathway databases. Among 18 coexpression relations
derived from the implication networks, 11 interactions specific to smokers were confirmed (Fig.
5.5A and 5.5B). The FDR of the smoking-mediated coexpression networks derived is 0.01.
These results indicate that implication networks can reveal biologically relevant gene
associations.

Figure 5.5. Smoking-mediated coexpression relations among the signature genes and lung cancer
hallmarks. Gene coexpression patterns specific to smokers (A) and non-smokers (B) derived by the
implication network algorithm (P < 0.05) in both training and test sets (FDR = 0.01). The biological
interpretation of the implication relations are described in (C). Interactions reported in literature retrieved
from Pathway Studio (D). The stability of smoking-mediated networks as evaluated with random subsets
of patients from the training cohort in 100 iterations (E).
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Results from the stability test of the smoking-mediated coexpression networks (Fig. 5.5A
and 5.5B) show that the implication network algorithm is stable as most of the coexpression
relations (about 70%) could be derived using as few as half of the training samples (Fig. 5.5E)

5.9 Experiment Validation
We further confirm the biological aspect of smoking-mediated gene coexpression relations
derived from the implication networks and the perturbation of signaling pathway mechanisms in
smokers among the identified signature genes and hallmark genes using the expression
quantified from cell lines. H23 and BEAS-2B cells were exposed to NNK for 15 minutes, one
hour, and 16 hours.

Then, qRT-PCR low-density arrays were used to analyze the gene

expressions in the NNK-treated cells. On the qRT-PCR data normalized with POLR2A, gene
expression fold changes of the genes in treated cell lines versus control were computed.
Based on the fold changes computed for the signature genes and the hallmarks observed
in the NNK-treated H23 cell lines, coexpression relations among the 7 signature genes and the six
hallmarks were derived. These represented the observed perturbations among the signature
genes and signaling pathway mechanism specific for smokers.

Comparing the observed

perturbations with coexpression relations unique for smokers (Fig. 5.5A), results showed that the
coexpression relations derived with the implication networks in smokers were confirmed by the
coexpression relations observed in NNK-treated H23, at different time points (Fig. 7).

Figure 5.6. Coexpression relations observed in the NNK-treated H23 cell lines for 15 minutes (A), 1
hours (B), and 16 hours (C).
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5.10 Conclusions
This study examined the implication network-based model discussed in Chapter 4 in a different
scenario. Instead of modeling disease-mediated coexpression networks at the genome-wide
scale, smoking-mediated coexpression networks were constructed on a subset of genes
associated with smoking and lung cancer survival. From the smoking-mediated coexpression
networks derived, a smoking-associated 7-gene prognostic signature that co-regulated with major
lung cancer signaling proteins were identified. The identified 7-gene signature showed strong
implications in providing accurate estimate for lung cancer survival and risk of diagnose with
lung cancer in smokers. The 7-gene defined prognostication also showed strong association with
smoking and smoking cessation.

Furthermore, the 7-gene prognostic model also appeared to be

a more accurate prognostic factor than commonly used clinical factors for lung cancer.
Using the same methodology, a 6-gene and an 8-gene smoking-associated prognostic
signature were also identified from having direct coexpression relations with different major lung
cancer signaling hallmarks (Table 5.4). The prognostic performance of the 6-gene and 8-gene
signatures was comparable with the 7-gene signature (Fig. 5.7).

Table 5.4. 6-gene and 8-gene smoking-associated signatures identified using the implication
network-based methodology.

Signature

6-gene signature
8-gene signature

Hallmarks
MET, EGF, KRAS,
TP53, E2F1, E2F4
MET, EGF, EGFR,
KRAS, E2F2, E2F5

Identified Signature Genes
HERC3, NUPR1, SEMA3C, EEF1B2,
SOSTDC1, TFAP2A
LUC7L3, CRTAC1, CYP3A4, GPRC5C,
HOMER1, PIGN, SEMA3C, EEF1B2
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Figure 5.7. Prognostic performance of the 6-gene and 8-gene signature identified with the networkbased methodology on patient cohorts from the Director’s Challenge Study [2]. Using multivariate
Cox proportional hazard model fitted with the 6 genes, the risk score giving the best predicted on the 3year ROC curve (value of -15.36) generated significant patient stratification in both the training and test
cohort (A,B) and smokers in training and test cohorts (C,D). Similarly, on the 8-gene fitted Cox model,
the mean of risk scores from training samples (value of -5.31) generated patients into two risk groups with
significantly distinct survival outcome in the training and test cohorts with all patients (E,F) and smoker
patients only (G,H).

In comparison with the clinical covariates, the 6-gene and 7-gne prognostic power was
comparable to one another (Table 5.5) but the 8-gene signature did not give better prognostic
power than clinical factors.
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Table 5.5. Multivariate Cox analyses of the 6-gene expression-defined prognostication and major
clinical covariates in smoking lung cancer patients in the test cohort.

Variable*
P-value Hazard Ratio (95% CI)ψ
Analysis without 6-gene prognostic prediction
Gender (Male)
0.55
1.17 (0.70, 1.95)
Age at diagnosis (>60)
0.35
1.31 (0.74, 2.29)
Tumor differentiation
Moderately differentiated
0.30
0.63 (0.26, 1.51)
Poorly differentiated
0.89
1.06 (0.47, 2.38)
Cancer Stage
Stage II
1.54E-03
2.60 (1.44, 4.71)
Stage III
5.53E-05
4.48 (2.16, 9.29)
Analysis with 6-gene prognostic prediction
Gender (Male)
0.42
1.24 (0.74, 2.08)
Age at diagnosis (>60)
0.52
1.20 (0.68, 2.13)
Tumor differentiation
Moderately differentiated
0.39
0.68 (0.28, 1.64)
Poorly differentiated
0.89
0.94 (0.42, 2.15)
Cancer Stage
Stage II
7.30E-04
2.83 (1.55, 5.19)
Stage III
1.51E-05
5.36 (2.50, 11.46)
6-gene prognostic prediction
0.04
1.89 (1.04, 3.43)
* Gender was a binary variable (0 for female and 1 for male); age at diagnosis was a binary variable (0 for < 60
years old and 1 otherwise); tumor grade was categorical variable of 3 categories (Well [as the reference group],
Moderately, and Poorly differentiated); cancer stage was categorical variable of 3 categories (Stage I [as the
reference group], Stage II, and Stage III).
ψ
denotes confidence interval.

Results from this study showed that the 7-gene smoking-associated signature is highly
potential to be used to develop clinical gene test to screen smokers for risk of developing lung
cancer and provide a precise prognostic test for smoking lung cancer patients. This would be
beneficial to a large population of the lung cancer patients.
The application of the implication network-based methodology in this study again
demonstrated that the methodology correctly modeled the biologically perturbed coexpression
patterns. In this study, the coexpression patterns perturbed by smoking practices were correctly
modeled and validated with coexpression relations observed from the experiments with NNKtreated cell lines.

Moreover, this study once more demonstrated that the integration of

biologically perturbed coexpression patterns with signaling pathway mechanisms lead to
identification of strong prognostic gene signatures.

Chapter 6
Evaluation with Boolean Implication
Networks and Bayesian Networks
Results presented in Chapter 4 and Chapter 5 demonstrated that the implication networks based
on prediction logic could efficiently model the disease-mediated gene coexpression networks for
signature genes identification. Furthermore, the coexpression patterns derived were successfully
validated with molecular interactions reported in the literature. Another similar formalism of
implication networks, i.e., Boolean implication networks were used in a meta-analysis to
discover relationships among genes for different species [80]. In contrast to small patient
cohorts we had studied, large sample of microarray data were used in their meta-analysis: 4,787
human, 2,154 mice, and 450 Drosophila. Moreover, the Boolean implication networks were
used as the framework to study the genomic evolution, where our framework was used for gene
selection. While implication networks could efficiently model the gene regulatory networks, it is
not as commonly known as the Bayesian networks in this research domain.
In this chapter, we will discuss the performance and characteristics of the employed
implication networks in comparison with the Boolean implication networks and Bayesian
networks. The comparison of the two implication networks in term of the size of the networks
will be presented in the first section, Section 6.1. Section 6.2 discusses the comparativeness of
both implication networks after fine-tuning the implication networks based on prediction logic.
Section 6.3 examines the biological robustness of networks derived from both implication
networks. To compare the employed implication networks with the Bayesian networks, we
evaluate the biological strength of the derived disease-mediated gene coexpression networks.
110
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The results are presented in Section 6.4. The last section, Section 6.5 provides a brief conclusion
on the comparison studies.

6.1 Comparison with Boolean Implication Networks
In the framework to derive Boolean implication networks, StepMiner algorithm [81] was first
used to automatically assign a threshold (t) for each gene. Based on the assigned threshold t, the
gene expression level was defined as up-regulated if the expression value is above t + 0.5; downregulated if the expression value is below t - 0.5. If the expression value is between t – 0.5 and t
+ 0.5, the expression level is defined as intermediate and will be ignored during the implication
relations derivation. The choice of the interval width (±0.5) is based on the standard deviations
of genes over all arrays, and the 5th percentile from the bottom is selected. In the data used in
their study, the standard deviation is a little less than 0.26. The interval is defined as two standard
deviations from the threshold, thus t ± 0.5. We adopted similar approach in deciding the width
for the interval width.
In our data, the standard deviations of all the genes (12,566 genes) ranged from 0.13 to
40.24. There were some outlier genes with very large standard deviation; this could be due to
noise (Fig 6.1A). After removing the outliers, the distribution of the standard deviations is a
little skewed toward the range of 0 to 0.5 (Fig 6.1B, 6.1C). The 5th percentile from the bottom
(value 0) of the distribution is 0.23. Therefore, after obtaining the threshold (t) from StepMiner,
we defined the gene as up-regulated if the expression value is t + 0.46, down-regulated if the
expression value is t – 0.46, or intermediate if the expression value lies between t – 0.46 and t +
0.46.
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(A) Box plot of standard deviation for all genes

(B) Box plot of standard deviations
after removing outliers

(C) Distribution of standard deviations
after removing outliers

Figure 6.1. Distribution of standard deviations for all the genes (A) and after removing
the outlier genes (B,C).

After defining the gene expression levels into up- or down-regulated by t + 0.46 and t 46, implication relations between the gene pairs were derived using the Boolean implication
networks proposed by Sahoo et al. [80] and the implication networks based on prediction logic
(Fig. 2.7). Implication relations were derived for good-prognosis group (patients who survived 5
years or longer after surgery) and poor-prognosis group (patients who died within 5 years after
surgery). By comparing the implication rule types in both prognosis group, implication relations
specific to each prognosis group were also obtained.
Results show that Boolean implication networks derived less coexpression relations than
those derived from implication networks based on prediction logic (Fig. 6.2), except for the
implication relations specific to poor-prognosis group.

After removing the samples with

expression falls within the intermediate range (t±0.46), the average sample size used for deriving
the implication relations is 23 (out of 125) for the poor prognosis group and 20 (out of 140) for
the good prognosis group. Since the number of samples in deriving the successful implication
relation between the pair of genes was small, these results are not reasonable to be further
investigated.

6 .Evaluation with Boolean Implication Networks and Bayesian Networks

113

No. of Coexpressions Relations
BooleanNet

100000000
10000000
1000000
100000
10000
1000
100
10
1
Poor Prognosis

Good Prognosis

Specific to Poor
Prognosis

GNet

Specific to Good
Prognosis

Figure 6.2. Comparison between Boolean implication networks (BooleanNet) and the implication
algorithms based on prediction logic (GNet) in term of the number of gene coexpression relations
derived.

6.2 Comparison after Parameters Tuning
For a reasonable comparison of both methods with larger and more representative sample, we
used two different approaches to define the expression level of genes as up- or down-regulated in
order to increase the sample size for deriving the implication relations. In the first approach, the
expression level of each gene was defined as up-regulated if the expression value is greater than
or equal to the mean of the gene in the cohort, and down-regulated otherwise. In the second
approach, the expression level of a gene was defined as up-regulated if the value is half the
standard deviation above the mean, down-regulated if it is half the standard deviation below the
mean, and intermediate if the expression value lies within half the standard deviation below or
above the mean.
In both approaches, the number of implication relations derived using the implication
algorithm based on prediction logic is larger than those derived from Boolean implication
networks. However, after tuning the minimum precision ( ∇ min ) in the induction algorithm
based on prediction logic, the number of interactions was reduced to the comparable scale as the
Boolean implication networks. (Fig. 6.3).
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Figure 6.3. Number of implication relations derived from Boolean implication network
(BooleanNet) and implication algorithm based on prediction logic (GNet) after tuning the minimum
precision parameter in data partitioned by mean only (A) and data partitioned by mean and half
the standard deviation (B).

The ∇ min was tuned because precision represents the prediction success of the
implication rule, which is comparative to the error rate parameter used to decide a successful
implication relation in the Boolean implication networks.

Results show that the networks

derived from implication networks based on prediction logic are comparable to those from
Boolean implication networks after tuning ∇ min .
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6.3 Assessment of Implication Networks with Biological
Databases
Having looked at the size of the derived coexpression networks, the biological aspect of the
derived coexpression networks was examined with the five gene collections from MSigDB. The
precision and false discovery rate of the derived coexpression networks for each prognosis group
was measured on the training data. Genes were partitioned into up- or down-regulated with the
mean expression of each gene in the cohort.

The two measurements from the Boolean

implication networks and the implication networks based on prediction logic tuned at ∇ min were
examined.
Results show that the precision for all derived networks were greater than 95%.
However, only precision of the implication networks with ∇ min = 0.78 was statistically
significant (P < 0.04).

The precision of the implication networks with ∇ min = 0.75 was

borderline significant (P < 0.06) and the Boolean implication networks was not significant (P <
0.21) (Fig. 6.4A). On the other hand, the false discovery rate of the derived networks was all
less than 5% (Fig. 6.4B). These results demonstrate that tuning the parameter ∇ min not only
reduces the size of derived implication networks but also affects the biological robustness of the
networks.
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Figure 6.4. Precisions (A) and false discovery rate (B) of the derived implication networks. An
asterisk (*) above the bar indicates that the precision is significantly (P < 0.05) higher than the null
precisions in 1,000 permutations.

6.4 Comparison with Bayesian Networks
As discussed in Section 2.2.5, Bayesian networks are the most common computational network
model for modeling biological networks. It was preferred in biomedical research studies over
other network models due to its characteristics in probabilistic structure and tolerance to noise in
biological data. Nevertheless, its shortcoming over implication networks in gene coexpression
networks is that it could not model feedback loop.

In this section, we will compare the

biological strength of the disease-specific coexpression networks derived from the implication
networks based on prediction logic and the Bayesian networks. Specifically, the precisions and
FDR of the disease-specific coexpression networks derived from both methodologies for the 21
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prognostic signatures identified using the network-based approach (Table B.1-B.3) were
compared.
On the patient cohorts from the Director’s Challenge Study [2], good-prognosis group is
defined as group of patients who survived 5 years or longer after surgery, whereas poorprognosis group is defined as group of patients who died within 5 years after surgery. For each
prognosis group, Bayesian networks were derived using the TETRAD IV 11 . As part of the
products from the TETRAD Project by the Carnegie Mellon University, TETRAD IV is the state
of the art application for causal models that implements Bayesian networks. TETRAD IV is
freely available in various versions, including the user-friendly GUI version and the command
line based executable JAR file. In our study, we employed the executable JAR file (version
4.3.10-3) as it allows us to program in scripts and makes the analysis for all 21 signatures more
efficient.
Results show that the precision of the disease-specific coexpression networks derived on
the training cohort using both methods are comparably high (Fig. 6.5A).

Among the 21

signatures, five signatures have precision of 1 for both methods. For the remaining 16 signatures,
the networks derived from Bayesian networks had precision comparable to those derived from
the implication networks. The precisions of networks from the two methods are significantly
different (P < 0.05, two-proportion z-tests) on two signatures (S8, S13).

For these two

signatures, the networks derived from the implication networks have higher proportion of true
relations among genes compared with those derived from the Bayesian networks.
Most of the disease-specific coexpression networks derived from both methods have low
FDR (FDR < 0.1; Fig. 6.5B).

While only one network (signature S7) derived with the

implication networks algorithm has FDR higher than 10%; two networks (signatures S2 and S11)
derived with the Bayesian network algorithm has FDR above 10%. Similar results are obtained
in the two testing cohorts (MSK and DFCI; Fig. 6.6). The precision and FDR of the diseasespecific coexpression networks derived using both methods are comparable to one another when
evaluated on each cohort independently.

11

http://www.phil.cmu.edu/projects/tetrad/
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Figure 6.5. Comparison of the disease-specific coexpression networks derived using implication
networks and Bayesian networks on the training cohorts from the Director’s Challenge Study [2] in
terms of precision (A) and false discovery rate (B) for the 21 prognostic signatures. An asterisk (*)
above the bar in (A) indicates that the precision of the two derived coexpression networks is statistically
significant (P < 0.05).
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Figure 6.6. Comparison precision and FDR of the disease-specific coexpression networks derived
using implication networks and Bayesian networks on two independent test cohorts. An asterisk (*)
above the bar in (A) indicates that the precision of the two derived coexpression networks is statistically
significant (P < 0.05).
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The more robust approach to evaluate the biological strength of the derived coexpression
relations in the networks would be based on the set of coexpression relations commonly present
in the networks derived on the training cohort and the two test cohorts. However, for all the 21
signatures, there was no relation commonly found in the disease-specific coexpression networks
derived in the training and test cohorts using Bayesian networks. On the other hand, the relations
derived from training cohort using the implication network algorithms could be successfully
reproduced in both independent test cohorts. The precision of the disease-mediate coexpression
networks common in three cohorts is 1 with statistical significance (P < 0.05) as evaluated in
1,000 random permutations for 18 of the 21 signatures (Fig. 6.7A). Furthermore, these networks
have FDR lower than 10% for all 21 signatures (Fig. 6.7B). Since there was no common relation
between the coexpression networks derived from both the training and two test cohorts using
Bayesian networks, the precisions are represented with zeros and false discovery rates are
represented with NAs (not applicable) in Fig. 6.7.

Figure 6.7. Comparison of the implication networks with the Bayesian networks on the diseasespecific coexpression relations commonly found on the three studied cohorts. The precision is zero
for the Bayesian networks for all 21 signatures in (A) and the FDR is NA in (B) as no relation was
commonly derived in all three cohorts. The asterisk (*) above the bar in (A) indicates that the precision is
significantly (P < 0.05) greater than null precisions in 1,000 permutations.
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For the 7-gene smoking-associated signature identified in Chapter 5, seven relations were
obtained on the smoking-mediated coexpression networks on the training cohort and 10 relations
were obtained on the test cohort [123].

Among these relations, only one smoker-specific

coexpression relation was commonly found in both the training and test cohort (Fig. 6.8C). In
comparison, with the implication networks algorithm employed in our studies, 18 (17 smokerspecific, 1 non-smoker-specific) coexpressions were commonly derived in both the training and
test cohorts (Fig. 6.8A, 6.8B). The precision of the smoking-mediated coexpression networks
derived from both methods is 1 and 0.91 for Bayesian and implication networks respectively,
with no statistical difference (P < 0.75, two-proportion z-test).

Figure 6.8. Comparison of the smoking-mediated coexpression networks for the 7-gene smokingassociated signature from the implication networks and the Bayesian networks. 18 gene
coexpression relations specific to smokers (A) and non-smokers (B) derived by the implication networks
algorithms commonly present in both training and test cohort. Only one smoker-specific coexpression
relations was commonly derived by Bayesian networks in both training and test cohort (C). (D) lists the
interpretation of various relations in the networks.
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Conclusions

As discussed at the beginning of the chapter, Boolean implication networks were applied for
large scale evolutionary conservation study of genes interactions. Its objective was to explore
the biological meaningful relationships among genes for a species or between different species
[80]. On the other hand, our applications focused on integrating genes interactions to study how
genes change in healthy and disease states and used for gene signatures discovery. Despite the
differences of the applications and objectives, the theoretical constructions of both implication
networks are similar and worth to be compared.
In the application of the Boolean implication networks, no further information was given
on fine tuning the parameters for deriving a successful implication relation. The two statistics
used to derive an implication relations are tested against a constant value (3 for the first statistics
and 0.1 for the error rate). On the other hand, the minimum requirements for scope (Up) and
precision ( ∇ min ) in the implication algorithm adopted in our studies could be adjusted according
to the sample size or users’ specification. This makes the algorithm we had adopted more
flexible.

In addition, results from the three comparison studies also demonstrate that the

implication networks implemented in our studies is comparable to the Boolean implication
networks. The size and biological robustness of the derived networks is comparable after tuning
the ∇ min parameter of the algorithm. Most importantly, in the lung cancer patient cohorts used
in the study, the coexpression relations in the derived Boolean implication networks do not
involved with most of the major lung cancer hallmarks. This makes the selection of marker
genes with crosstalk to signaling pathways unfeasible.
In the comparison to Bayesian networks, implication networks employed in our studies
could reveal more true biological relations than the Bayesian networks. Although the precision
and FDR of the disease-specific coexpression networks are comparable in both methods when
evaluated on the training and test cohorts separately, the relations derived with Bayesian
networks in the training cohort could not be reproduced on the test cohort. On the other hand,
the gene coexpression relations derived with implication networks in the training cohort could be
reproduced in the testing cohorts with low false discovery rate.

Chapter 7
Contributions and Future Work
7.1 Contributions
Lung cancer remains the leading cause of death worldwide. In search for a cure for this fatal
disease, it is important to identify clinically relevant prognostic biomarkers in order to develop
personalized medicine. More importantly, the discovered biomarkers may reveal fundamental
molecular mechanisms of this fatal disease, and improve our knowledge of why patients with
certain tumor molecular characteristics have a poor clinical outcome and how to improve their
survival time.

Studies of biomarker discoveries had been enhanced proficiently by the

emergence and development of microarray technologies.

Our studies provided a few

contributions to this research area.
The first contribution of our studies is the development of a hybrid system for the
identification of prognostic genes for lung cancer with traditional statistics and feature selection
methods.

Results demonstrated that the systematic combinatorial framework of multiple

traditional methods in the hybrid model provided improved performance over traditional
methods when being applied alone.

The 12-gene signature identified from this hybrid model

showed better prognostic performance than published signatures.

The 12-gene expression-

defined prognostic model precisely identified risk for stage I and II patients for different
treatments, and accurately predicted chemotherapy drug response. These results implied the
clinical utility of the 12-gene signature in the development of personalized therapy.
The second contribution of our works is the extensive identification of prognostic
signatures for lung cancer using a network-based hybrid system. The novel network model
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employed in the second system is the implication networks based on prediction logic. This is an
innovative application of using implication networks to model the genome-wide diseasemediated coexpression networks. The implication network-based system not only efficiently
scales to the entire genome, but also conveniently couples with information from signaling
pathways for the identification of prognostic genes. Using this system, we extensively explored
the prognostic signatures of the whole genomic space and discovered 21 signatures with better
performance than all published signatures in prognostic categorization on the same patient
cohorts. The prognostication evaluation of the signatures were carried out on patients with all
tumor stages, stage I only, and stage I without receiving chemotherapy, which was the prognostic
capacity never been reported till date. Results also implied that the 21 identified gene signatures
could potentially provide a more precise patient selection scheme in stage I patients for adjuvant
chemotherapy in personalized lung cancer treatment. Furthermore, the coexpression patterns
derived from the implication networks were also successfully validated with molecular
interactions reported in the literature.
The third contribution of our studies included the discovery of a 7-gene smokingassociated signature using the implication network-based system. Smoking has been known to
be highly associated with lung cancer but yet is not an established clinical factor used in lung
cancer prognosis. Our discovery contributed more information to the genes with association to
both smoking and lung cancer survival.

From our study, the identified 7-gene smoking-

associated signature showed strong prognostication for smoking lung cancer patients and
accurately identified high-risk patients from a cohort of smokers.

The smoking-mediated

coexpression networks derived from the implication networks were being validated in
experiment by our collaborators.

These results implied that the 7-gene signature could

potentially be used to develop gene test for more precise prognosis for smoking lung cancer
patients, which occupies 90% of all lung cancer patients. It could be used to screen for risk of
developing lung cancer for smokers, which could raise cautions to smokers and help advocating
them on quitting smoking to reduce health risks.

7. Contributions and Future Work

125

7.2 Future Work
Results from the comparison studies with the Boolean implication networks presented in Chapter
6 lead us to the future analysis of the methodology through examination of the characteristics of
the two implication networks as affected by different parameters, such as the minimum
precision, minimum scope, as well as the weights associated with the implication rule and its
logical equivalence. In addition, we could also study the comparativeness of the parameters in
both algorithms. Through these examinations, we hope to acquire the set of parameters for the
derivation of a smaller gene coexpression networks with strong biological robustness (high
precision with statistical significance and low false discovery rate) for this research domain to
identify marker genes for complex diseases.
Results from Chapter 6 had demonstrated that the number of samples used for deriving
the implication networks affects the implication networks derived. Another direction to study
the methodology in the future is to study the use of other approach to define genes as up- or
down-regulated and the effects on the implication networks derived for prognostic genes
identifications. Instead of using mean alone as the threshold to define gene as up- or downregulated, alternative approach such as the more stringent threshold with standard deviations
could be used. However, this would lead to the removal of patient samples that do not pass the
threshold, which would lead to smaller sample size.

Appendix A
Published Lung Cancer Molecular Classifiers and
Gene Signatures
Table A.1: Summary of gene selection and classification methods of molecular classifiers
reported in (Shedden et al, 2008).
Molecular
Classifier*

Shedden A

Number of
signature genes

~ 9591 Genes

Gene selection method(s)

Clustering analysis
SAM, Maximizing Chi-Square
analysis (MCA, univariate Cox
model and k-mean clustering)
SAM, Maximizing Chi-Square
analysis (MCA, univariate Cox
model and k-mean clustering)

Classification
method(s)
Ridged Cox
proportional hazard
model
Binary Tree-Structured
Vector Quantization
(BTSVQ)
Binary Tree-Structured
Vector Quantization
(BTSVQ)

Shedden C

23 Genes

Shedden D

37 Genes

Shedden E

1 Gene

Gene Expression Fold Change

Shedden F

42 Genes

Univariate Cox Model

Shedden G

38 Genes

Univariate Cox Model

Shedden H

252 Genes

Scoring and filtering on set of
mitosis genes

Majority vote

Shedden J

5 Genes

Univariate Cox model (Chen et
al, NEJM 07)

Ridged Cox
proportional hazard
model

Shedden K

16 Genes

Univariate Cox model (Chen et

Ridged Cox
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Post-hoc split of
expression of one gene
Principal Components
and Cox Model
Principal Components
and Cox Model
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al, NEJM 07)

Shedden L

9 Genes
(from 80 Genes)

Principal Components (Potti et
al, NEJM 06)

Shedden
M

45 Genes
(from 80 Genes)

Principal Components (Potti et
al, NEJM 06)

Shedden N

80 Genes

Principal Components (Potti et
al, NEJM 06)

proportional hazard
model
Ridged Cox
proportional hazard
model
Ridged Cox
proportional hazard
model
Ridged Cox
proportional hazard
model

*Gene signatures A-H were identified in (Shedden et al, 2008). Gene signatures J and K were identified
in (Chen et al, 2007). Gene signatures L, M, and N were identified in (Potti et al, 2006).

Table A.2: 14 published lung cancer gene signatures evaluated in GSEA in Chapter 3.
Signature Name
(GSEA)

Beer_50g
Bhattacharjee_150g
Boutros_6g
Chen_5g
Guo_35g
Lau_3g
Lu_64g
Potti_133g
Raponi_50g
Shedden_MA
Shedden_MB
Shedden_MC
Shedden_MD
Shedden_MH

First Author

Publication
PubMed ID

Beer, DG
Bhattacharjee, A
Boutros, PC
Chen, HY
Guo, L
Lau, SK
Lu, Y
Potti, A
Raponi, M
Shedden, K
Shedden, K
Shedden, K
Shedden, K
Shedden, K

PMID:12118244
PMID:11707567
PMID:19196983
PMID:17202451
PMID:16740756
PMID:18065728
PMID:17194181
PMID:16899777
PMID:16885343
PMID:18641660
PMID:18641660
PMID:18641660
PMID:18641660
PMID:18641660

No. of
Signature
Genes/Prob
es
50
150
6
5
35
3
64
133
50
13830
52
26
42
313

No. of Genes
matched in
GSEA (By gene
symbol)
45
130
6
5
34
3
62
129
44
8319
50
23
34
244
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Significant Prognostic Signatures Identified Using Network-based Models
Table B.1: Prognostic signatures identified with Approach 1 that generated significant stratifications in patients with all
stages, stage I only, and stage I without receiving chemotherapy.
No.

Size of
Signature

S1

21

S2

19

S3

24

S4

32

Hallmarks

Signature genes

MET, EGF, KRAS,
RB1, E2F1, E2F5
EGF, EGFR, KRAS,
TP53, E2F3, E2F4
EGF, KRAS, TP53,
E2F1, E2F2, E2F4

HSPA9, PRDX6, SUPT7L, LEPROT, MPI, QPCT, SLC39A8, ADH1B, MTX1, RAD17, HIPK1, ZFR, CLIC2,
TFPI, HEXA, LYST, DYNLRB1, GCC1, CPEB1, ATP1A1, ABHD11
TOMM34, RPS6KA1, ADD2, MPPED1, DNAJC4, IL12RB2, ICA1, THY1, LOC399491, FHL1, WDR43,
LRRC23, MRPL13, ZC3H7A, GRHL2, APOA2, CPEB1, LOC100294391, ATP1A1
EEF1B2, TOMM70A, TOMM34, IRF3, DDT, RPS6KA1, SC65, SMAD3, PPM1E, MOCS3, DNAJC4, DNAJA2,
GRK6, ZNF592, THY1, FHL1, ACTA2, GRM8, GRHL2, APOA2, CPEB1, FBXO31, PDCD1LG2, HDLBP
PRDX6, ANXA6, TOMM70A, TOMM34, IRF3, RPS6KA1, KATNA1, MPHOSPH9, CCDC9, ZNF141,
SCNN1G, DNAJA2, ABCF2, HBS1L, APLP1, ITCH, MTX1, GRK6, NUP214, ANXA9, ELN, ZFR, ZNF592,
ACTA2, GRM8, NRN1, APOA2, CPEB1, PDCD1LG2, MUM1, HDLBP, RING1

EGF, KRAS, TP53,
E2F1, E2F2, E2F5
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Table B.2: Prognostic signatures identified with Approach 2 that generated significant stratifications in patients with all
stages, stage I only, and stage I without receiving chemotherapy.
No.

Size of
Signature

Hallmarks

Signature genes

S5

5

MET, EGFR, E2F2,
KRAS, TP53, E2F1, E2F3

CD86, LHX2, GBX1, HEMK1, CPEB1

Table B.3: Prognostic signatures identified with Approach 3 that generated significant stratifications in patients with all
stages, stage I patients only, and stage I patients without receiving chemotherapy.
No.
S6
S7
S8
S9
S10
S11
S12
S13
S14
S15

Size of
Signature
4
7
33
23
7
19
7
10
15
21

Coexpressed
Signaling
Hallmarks
MET, EGF, EGFR,
KRAS, TP53, E2F3
MET, EGF, EGFR,
KRAS, E2F2, E2F3
MET, EGF, KRAS,
TP53, E2F1, E2F2
MET, EGF, KRAS,
E2F1, E2F3, E2F5
EGF, EGFR, KRAS,
TP53, RB1, E2F2
EGF, EGFR, KRAS,
TP53, E2F3, E2F4
EGF, EGFR, TP53,
RB1, E2F1, E2F2
EGF, KRAS, TP53,
RB1, E2F1, E2F2
EGF, KRAS, TP53,
RB1, E2F1, E2F4
EGF, KRAS, TP53,
RB1, E2F1, E2F5

Signature genes
CD86, ICA1, RPAP3, CPEB1
ANXA6, SLC17A7, CD86, GAS7, TAF4, ARNT, CPEB1
EEF1B2, SNRPD2, PRDX6, ANXA6, TOMM70A, NIPSNAP1, IL13RA1, IRF3, DDT, ABCC4, RPS6KA1, SMAD3,
CD86, CCDC9, OPRL1, CLDN6, DNAJA2, CCL19, MTX1, MAPK9, ANXA9, ZFR, THY1, SFRS2B, IVD , MKRN2,
GRHL2, CPEB1, FBXO31, PDCD1LG2, C20orf30, MUM1, OR1F1
HSPA9, ANXA6, MPI, ACTL6A, RPS6KA1, RTCD1, SLC12A2, CCDC9, NDUFAF3, FLT3LG, ANXA9, ZFR,
CLIC2, SOSTDC1, TRMU, TCF3, DYNLRB1, CPEB1, C20orf46, LOC100294391, ATP1A1, MUM1, ABHD11
RPL18, VIPR2, MOCS3, DNAJC4, ADAMTSL3, WDR12, HDLBP
TOMM34, RPS6KA1, ADD2, MPPED1, DNAJC4, IL12RB2, ICA1, THY1, LOC399491, FHL1, WDR43, LRRC23,
MRPL13, ZC3H7A, GRHL2, APOA2, CPEB1, LOC100294391, ATP1A1
MOCS3, DNAJC4, CCBP2, THY1, SFRS2B, PUM2, HDLBP
PRDX6, MOCS3, OPRL1, HBS1L, MTX1, ZFR, SPIN1, CPEB1, OR1F1, HDLBP
DDT, MOCS3, MPPED1, DNAJC4, RGL1, CEP57, THY1, TFPI, LRRC23, MRPL13, CPEB1, FBXO31, ATP1A1,
HDLBP, SFTPB
RPL30, PRDX6, SNX2, LEPROT, MPI, KATNA1, SLC39A8, HBS1L, MTX1, ELN, ZFR, ANGEL1, TFPI, LRRC23,
NRN1, SLC35F2, HMBOX1, CPEB1, ATP1A1, GINS2, HDLBP
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S16
S17
S18
S19
S20
S21

130

24

EGF, KRAS, TP53,
E2F1, E2F2, E2F4

32

EGF, KRAS, TP53,
E2F1, E2F2, E2F5

6
3
9
9

EGF, KRAS, TP53,
E2F2, E2F3, E2F5
EGF, KRAS, RB1,
E2F1, E2F3, E2F5
EGFR, KRAS, RB1,
TP53, E2F1, E2F2
EGFR, KRAS, RB1,
E2F5, TP53, E2F2,

EEF1B2, TOMM70A, TOMM34, IRF3, DDT, RPS6KA1, SC65, SMAD3, PPM1E, MOCS3, DNAJC4, DNAJA2,
GRK6, ZNF592, THY1, FHL1, ACTA2, GRM8, GRHL2, APOA2, CPEB1, FBXO31, PDCD1LG2, HDLBP
PRDX6, ANXA6, TOMM70A, TOMM34, IRF3, RPS6KA1, KATNA1, MPHOSPH9, CCDC9, ZNF141, SCNN1G,
DNAJA2, ABCF2, HBS1L, APLP1, ITCH, MTX1, GRK6, NUP214, ANXA9, ELN, ZFR, ZNF592, ACTA2, GRM8,
NRN1, APOA2, CPEB1, PDCD1LG2, MUM1, HDLBP, RING1
KIAA0040, KCNS3, KCNA4, COL14A1, CPEB1, RING1
HSPA9, ABHD11, C9orf156
TRAP1, PRMT2, MOCS3, DNAJC4, CCL8, TFCP2L1, LOH3CR2A, HDLBP, PKNOX2
TRAP1, VIPR2, TCP10, TBX1, CCL8, LDLR, WDR12, PRR15L, HDLBP

Appendix C
Disease-specific Coexpression Networks for the
Prognostic Signatures Identified Using Network-based
Models
Positive Implication (A => B)
(Up-regulation of gene A causes up-regulation of gene B)

Forward Negative Implication (A => ¬B)
(Up-regulation of gene A causes down-regulation of gene B)

Inverse Negative Implication (¬A => B)
(Down-regulation of gene A causes up-regulation of gene B)

Negative Implication (¬A => ¬B)
(Down-regulation of gene A causes down-regulation of gene B)

Positive Equivalence (A

B)

(Up-regulation of gene A causes up-regulation of gene B and
up-regulation of gene B causes up-regulation of gene A)

Negative Equivalence (A
¬B)
(Up-regulation of gene A causes down-regulation of gene B and
down-regulation of gene B causes up-regulation of gene A)

Figure C.1. Legend of expression relations of the disease-specific coexpression networks
represented in the six implication rules.
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Good Prognosis

Poor Prognosis

ABHD11

LEPROT

RB1

MPI

ZFR

QPCT

TFPI
ATP1A1

E2F5
DYNLRB1

MPI
SUPT7L

EGF

KRAS

SLC39A8

CLIC2

ADH1B

LYST

E2F1

CPEB1

RB1

HEXA

EGF

SUPT7L
E2F1

MTX1

Figure C.2. Disease-specific coexpression networks for signature S1 (precision = 0.71, FDR
= 0.08)

Good Prognosis

Poor Prognosis

ADD2

MRPL13

E2F4

TOMM34

ZC3H7A

CPEB1

EGFR

RPS6KA1

TP53

GRHL2

MPPED1
LRRC23

WDR43

APOA2

LOC399491

MPPED1

E2F4

KRAS

TOMM34

RPS6KA1

EGFR

ZC3H7A

E2F3

Figure C.3. Disease-specific coexpression networks for signature S2 (precision = 1, FDR =
0.10)
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Figure C.4. Disease-specific coexpression networks for signature S3 (precision = 1, FDR =
0.03)

Good Prognosis

Poor Prognosis

HBS1L

KATNA1

IRF3

RING1

HBS1L

MPHOSPH9

E2F5

ZFR
ZNF592

RING1

E2F2
ANXA9
ZFR

KRAS

MUM1

ACTA2

APLP1

ITCH

GRM8

DNAJA2

E2F1

PDCD1LG2

CCDC9

RPS6KA1

NUP214

MTX1

TP53

TP53

E2F5

ELN

TOMM70A

APOA2
APLP1

MTX1
PDCD1LG2

ABCF2

EGF

KRAS

ANXA9

CPEB1
PRDX6

Figure C.5. Disease-specific coexpression networks for signature S4 (precision = 1, FDR =
0.01)
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Figure C.6. Disease-specific coexpression networks for signature S5 (precision = 1, FDR =
0)

Figure C.7. Disease-specific coexpression networks for signature S6 (precision = 1, FDR =
0)
Good Prognosis

Poor Prognosis
E2F2
SLC17A7

SLC17A7

ARNT
EGF

EGFR
TAF4
KRAS
E2F3

MET
CD86
GAS7

Figure C.8. Disease-specific coexpression networks for signature S7 (precision = 0.86, FDR
= 0.10)

Appendix C

Figure C.9. Disease-specific coexpression networks for signature S8 (precision = 0.95, FDR
= 0.05)

Figure C.10. Disease-specific coexpression networks for signature S9 (precision = 1, FDR =
0.02)
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Figure C.11. Disease-specific coexpression networks for signature S10 (precision = 1, FDR
= 0.08)

Figure C.12. Disease-specific coexpression networks for signature S11 (precision = 1, FDR
= 0.06)

Figure C.13. Disease-specific coexpression networks for signature S12 (precision = 1, FDR
= 0)
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Figure C.14. Disease-specific coexpression networks for signature S13 (precision = 1, FDR
= 0)

Figure C.15. Disease-specific coexpression networks for signature S14 (precision = 1, FDR
= 0.01)
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Good Prognosis

Poor Prognosis
E2F5

KRAS

ZFR

ANGEL1

LEPROT

MTX1

CPEB1

HMBOX1

TP53

ATP1A1

GINS2

LRRC23

PRDX6

HBS1L

E2F5

TFPI

SLC35F2

TP53

SLC39A8

ZRN

ELN

CPEB1

GINS2

HMBOX1

MTX1

ANGEL1

ATP1A1

MPI

EGF

Figure C.16. Disease-specific coexpression networks for signature S15 (precision = 1, FDR
= 0.05)

Figure C.17. Disease-specific coexpression networks for signature S16 (precision = 1, FDR
= 0.03)
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Good Prognosis

Poor Prognosis

DNAJA2
ACTA2

NUP214

PDCD1LG2
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Figure C.18. Disease-specific coexpression networks for signature S17 (precision = 1, FDR
= 0.02)

Figure C.19. Disease-specific coexpression networks for signature S18 (precision = 1, FDR
= 0)
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Figure C.20. Disease-specific coexpression networks for signature S19 (precision = 1, FDR
= 0)

Figure. C.21. Disease-specific coexpression networks for signature S20 (precision = 1, FDR
= 0.05)

Figure C.22. Disease-specific coexpression networks for signature S21 (precision = 1,
FDR=0.001)
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